CUMULATIVE SUPPLEMENT 9
JAN'95-SEP'95

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DRUG INFORMATION RESOURCES

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

SUBSCRIBE NOW!

Available in March 1996

New 16th Edition

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION
1996

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- USP Monograph Title Additions or Changes
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Cumulative Supplement 9

SETEMBER 1995

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

CUMULATIVE SUPPLEMENT 9
SEPTEMBER 1995

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 15th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 15th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 16th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

The Uruguay Round Agreements Act (URAA), Public Law 103-465, extended the term of patents issued on or after June 8, 1995, from 17 years from date of issue to 20 years from date of filing. Patents in effect on, or based upon applications filed by, June 8, 1995, are entitled to 17 years from date of issue or 20 years from date of filing, whichever is greater. On June 7, 1995, the Patent and Trademark Office (PTO) published a notice in the *Federal Register* (60 FR 30069) that established the method for calculating the patent term expiration date for any patent subject to both the terms of the URAA and the patent term extension provisions at title 35, U.S.C. § 156. FDA published a notice in the *Federal Register* on July 21, 1995, (60 FR 37652) announcing that it would not publish

in this publication patent expiration dates that the NDA applicant submitting the information stated were not calculated in accordance with the PTO method for determining the correct patent expiration date.

Both PTO's determination of the correct relationship between the extension of patents under the URAA and patent term extensions under title 35, U.S.C. § 156, and FDA's refusal to publish patent expiration dates that are not consistent with the PTO determination have been challenged. On October 16, 1995, the U.S. District Court for the Eastern District of Virginia issued an Opinion and Order finding that PTO had misinterpreted the Patent Code, and that PTO's determination of June 7, 1995, is invalid and unenforceable. The court ordered FDA to publish the patent dates it had, by its July 21, 1995, notice, refused to publish. Therefore, because of the court's order, and pending final resolution of appeals from the October 16, 1995, decision, FDA is publishing the patent term expiration dates that NDA applicants have told FDA are not consistent with PTO's June 7, 1995, determination. Because the district court decision may be reversed upon appeal, users of this publication should consult the most recent supplement and are encouraged to confirm that patent information upon which they intend to rely is current.

1.3 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated

as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.4 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BOOTS PHARMACEUTICALS INC (BOOTS)	KNOLL PHARMACEUTICAL COMPANY SUB BASF CORPORATION (KNOLL PHARM)
BRIAN PHARMACEUTICALS INC (BRIAN)	HYGENICS PHARMACEUTICALS INC (HYGENICS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
DORSEY LABORATORIES DIV SANDOZ WANDER INC (DORSEY)	SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS CORP (SANDOZ)
MARION MERRELL DOW INC (MARION MERRELL DOW)	HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)
MERRELL DOW PHARMACEUTICALS INC SUB DOW CHEMICAL CO (MERRELL DOW)	HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)
MILES PHARMACEUTICAL DIV MILES INC (MILES)	BAYER CORPORATION (BAYER)
PENNEX PHARMACEUTICALS INC (PENNEX)	MORTON GROVE PHARMACEUTICALS INC (MORTON GROVE)
TAP PHARMACEUTICALS INC (TAP PHARMS)	TAP HOLDINGS INC (TAP HOLDINGS)

1.5 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is now available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1994) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1994	MAR 1995	JUN 1995	SEP 1995
DRUG PRODUCTS LISTED	9141	9195	9221	
SINGLE SOURCE	2178 (23.8%)	2186 (23.8%)	2186 (23.7%)	
MULTISOURCE	6963 (76.2%)	7009 (76.2%)	7035 (76.3%)	
THERAPEUTICALLY EQUIVALENT	6330 (69.2%)	6380 (69.4%)	6399 (69.4%)	
NOT THERAPEUTICALLY EQUIVALENT	453 (5.0%)	453 (4.9%)	452 (4.9%)	
EXCEPTIONS[1]	180 (2.0%)	176 (1.9%)	184 (2.0%)	
NEW MOLECULAR ENTITIES APPROVED	--	2	10	
NUMBER OF APPLICANTS	534	541	559	

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

> ADD >	ACARBOSE				
> ADD >	TABLET; ORAL				
> ADD >	PRECOSE				
> ADD >	BAYER	50MG		N20482 001	SEP 06, 1995
> ADD >	+	100MG		N20482 002	SEP 06, 1995
> ADD >					

	ACEBUTOLOL HYDROCHLORIDE				
	CAPSULE; ORAL				
	ACEBUTOLOL HCL				
AB	MYLAN	EQ 200MG BASE		N74288 001	APR 24, 1995
AB		EQ 400MG BASE		N74288 002	APR 24, 1995
	SECTRAL				
AB	WYETH AYERST	EQ 200MG BASE		N18917 001	DEC 28, 1984
AB	+	EQ 400MG BASE		N18917 003	DEC 28, 1984

	ACETAMINOPHEN; BUTALBITAL; CAFFEINE				
	TABLET; ORAL				
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE				
AB	WEST WARD PHARM	325MG;50MG;40MG		N89718 001	JUN 12, 1995

	ACETAMINOPHEN; CODEINE PHOSPHATE				
	SOLUTION; ORAL				
	ACETAMINOPHEN AND CODEINE PHOSPHATE				
AA	BARRE	120MG/5ML;12MG/5ML		N85861 001	
	APAP W/ CODEINE				
AA	BARRE	120MG/5ML;12MG/5ML		N85861 001	
	TABLET; ORAL				
	ACETAMINOPHEN AND CODEINE PHOSPHATE				
AA	KV PHARM	300MG;30MG		N85288 001	
AA		300MG;60MG		N85365 001	
		325MG;15MG		N85364 001	
		325MG;45MG		N85363 001	
	@	300MG;30MG		N85288 001	
	@	300MG;60MG		N85365 001	

	ACETAMINOPHEN; CODEINE PHOSPHATE				
	TABLET; ORAL				
	ACETAMINOPHEN AND CODEINE PHOSPHATE				
	@ KV PHARM	325MG;15MG		N85364 001	
	@	325MG;45MG		N85363 001	
AA	MIKART	650MG;30MG		N89231 001	MAR 03, 1986
	+	650MG;30MG		N89231 001	MAR 03, 1986
	+ ROXANE	500MG;15MG		N89511 001	APR 25, 1989
	+	500MG;30MG		N89512 001	APR 25, 1989
	+	500MG;60MG		N89513 001	APR 25, 1989
	@	500MG;15MG		N89511 001	APR 25, 1989
	@	500MG;30MG		N89512 001	APR 25, 1989
	@	500MG;60MG		N89513 001	APR 25, 1989
	PHENAPHEN-650 W/ CODEINE				
AA	+ ROBINS AH	650MG;30MG		N85856 001	
	@	650MG;30MG		N85856 001	

	ACETAMINOPHEN; HYDROCODONE BITARTRATE				
	TABLET; ORAL				
	ANEXSIA				
AA	BOEHRINGER MANNHEIM	500MG;5MG		N89160 001	APR 23, 1987
AA	KING PHARMS	500MG;5MG		N89160 001	APR 23, 1987
	ANEXSIA 7.5/650				
AA	BOEHRINGER MANNHEIM	650MG;7.5MG		N89725 001	SEP 30, 1987
AA	KING PHARMS	650MG;7.5MG		N89725 001	SEP 30, 1987
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
AA	HALSEY	500MG;5MG		N89554 001	JUN 12, 1987
	@	500MG;5MG		N89554 001	JUN 12, 1987
AA	KING PHARMS	500MG;5MG		N40084 002	JUN 01, 1995
AA		750MG;7.5MG		N40084 001	JUN 01, 1995

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

> ADD >	AA	+ MIKART	650MG;10MG	N81223 001	MAY 29, 1992
> ADD					
> ADD >	AA	WATSON LABS	650MG;7.5MG	N40094 001	SEP 29, 1995
> ADD >					
> ADD >	AA		650MG;10MG	N40094 002	SEP 29, 1995
> ADD >					

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
ROXILOX

AA	ROXANE	500MG;5MG	N40061 001	JUL 03, 1995

TABLET; ORAL
OXYCET

AA	HALSEY	325MG;5MG	N87463 001	DEC 07, 1983
AA	MALLINCKRODT	325MG;5MG	N87463 001	DEC 07, 1983

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL
DIAMOX

> DLT >		+ STORZ OPHTHALM	500MG	N12945 001	
> ADD >		@	500MG	N12945 001	
> ADD >		+	500MG	N12945 003	APR 25, 1995
> ADD >					

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

AP	BEDFORD	EQ 500MG BASE/VIAL	N40089 001	FEB 28, 1995

DIAMOX

AP	+ STORZ OPHTHALM	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL
ACETYLCYSTEINE

AN	DUPONT MERCK	10%	N71364 001	MAY 01, 1989
AN		20%	N71365 001	MAY 01, 1989
AN	FAULDING	10%	N71364 001	MAY 01, 1989
AN		20%	N71365 001	MAY 01, 1989
AN	LUITPOLD	10%	N72489 001	JUL 28, 1995
AN		20%	N72547 001	JUL 28, 1995

ADENOSINE

INJECTABLE; INJECTION
ADENOSCAN

+	MEDCO RES	3MG/ML	N20059 001	MAY 18, 1995

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

> ADD >	AN	PACO	EQ 0.083% BASE	N73533 001	SEP 26, 1995
> ADD >					

SYRUP; ORAL
ALBUTEROL SULFATE

> ADD >	AA	BARRE	EQ 2MG BASE/5ML	N74454 001	SEP 25, 1995
> ADD >					

> ADD > ALENDRONATE SODIUM

TABLET; ORAL
FOSAMAX
MERCK

> ADD >		EQ 10MG BASE	N20560 001	SEP 29, 1995
> ADD >				
> ADD >	+	EQ 40MG BASE	N20560 002	SEP 29, 1995
> ADD >				

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM			
AB	CHELSEA LABS	**0.25MG**	**N74456 001**	AUG 31, 1995
AB		**0.5MG**	**N74456 002**	AUG 31, 1995
AB		**1MG**	**N74456 003**	AUG 31, 1995

ALPROSTADIL

INJECTABLE; INJECTION

	CAVERJECT			
	UPJOHN	0.01MG/VIAL	N20379 001	JUL 06, 1995
+		0.02MG/VIAL	N20379 002	JUL 06, 1995

ALSEROXYLON

TABLET; ORAL

> DLT >	RAUWILOID			
> DLT >	* 3M	2MG	**N08867 001**	
> DLT >	@	2MG	N08867 001	
> ADD >				

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

	AMANTADINE HCL			
AA	PHARM ASSOC	**50MG/5ML**	**N74509 001**	JUL 17, 1995

AMIKACIN SULFATE

INJECTABLE: INJECTION

	AMIKACIN			
AP	DUPONT MERCK	**EQ 50MG BASE/ML**	**N63350 001**	JUL 30, 1993
AP		**EQ 250MG BASE/ML**	**N63350 002**	JUL 30, 1993
AP +	ELKINS SINN	**EQ 50MG BASE/ML**	**N63274 001**	MAY 18, 1992

AMIKACIN SULFATE

INJECTABLE: INJECTION

	AMIKACIN			
AP +	ELKINS SINN	**EQ 250MG BASE/ML**	**N63275 001**	MAY 18, 1992
	AMIKACIN SULFATE			
AP	ELKINS SINN	**EQ 50MG BASE/ML**	**N63274 001**	MAY 18, 1992
AP		**EQ 250MG BASE/ML**	**N63275 001**	MAY 18, 1992
AP	FAULDING	**EQ 50MG BASE/ML**	**N63350 001**	JUL 30, 1993
AP		**EQ 250MG BASE/ML**	**N63350 002**	JUL 30, 1993
AP	SANOFI WINTHROP	**EQ 250MG BASE/ML**	**N64098 001**	JUN 26, 1995
AP		**EQ 250MG BASE/ML**	**N64099 001**	JUN 20, 1995
	AMIKIN			
AP	APOTHECON	**EQ 50MG BASE/ML**	**N62311 001**	
AP		EQ 50MG BASE/ML	N62311 001	
AP +		**EQ 250MG BASE/ML**	**N62311 002**	
AP		**EQ 250MG BASE/ML**	N62311 002	
AP +	@	EQ 50MG BASE/ML	N62562 001	SEP 20, 1984
	@	EQ 250MG BASE/ML	N62562 002	SEP 20, 1984
	@ BRISTOL	EQ 50MG BASE/ML	N62562 001	SEP 20, 1984
	@	EQ 250MG BASE/ML	N62562 002	SEP 20, 1984

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ APOTHECON		EQ 5MG BASE/ML	N50618 002	NOV 30, 1987
@		EQ 10MG BASE/ML	N50618 001	NOV 30, 1987
@ BRISTOL		EQ 5MG BASE/ML	N50618 002	NOV 30, 1987
@		EQ 10MG BASE/ML	N50618 001	NOV 30, 1987

AMINOPHYLLINE

INJECTABLE; INJECTION

	AMINOPHYLLINE			
AP	FUJISAWA	**25MG/ML**	**N87200 001**	

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP	FUJISAWA	**25MG/ML**		**N88407 001**
	@	25MG/ML		JAN 25, 1984
	@	25MG/ML		N87200 001
				N88407 001
AP	KING PHARMS	**25MG/ML**		JAN 25, 1984
	@	25MG/ML		**N86606 001**
				N86606 001

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

	ABBOTT	**100MG/100ML**		**N88147 002**
				MAY 03, 1983
		200MG/100ML		**N88147 003**
				MAY 03, 1982
	+	100MG/100ML		N88147 002
				MAY 03, 1983
	+	200MG/100ML		N88147 003
				MAY 03, 1983

TABLET; ORAL

AMINOPHYLLINE

BD	PHOENIX LABS NY	100MG		N85409 001
BD		200MG		N85410 001
	@	100MG		N85409 001
	@	200MG		N85410 001

AMINOSALICYLATE SODIUM

POWDER; ORAL

P.A.S. SODIUM

> DLT > **AA**	CENTURY PHARMS	**4GM/PACKET**		**N80947 001**
> ADD >	@	4GM/PACKET		N80947 001

SODIUM AMINOSALICYLATE

> DLT > **AA**	HEXCEL	**100%**		**N80097 001**
> ADD >	@	100%		N80097 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

CORDARONE

	+ WYETH AYERST	50MG/ML		N20377 001
				AUG 03, 1995

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

AB	ROXANE	**150MG**		**N86090 001**
	@	150MG		N86090 001

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

	CIBA GEIGY	EQ 2.5MG BASE;10MG		N20364 002
				MAR 03, 1995
		EQ 5MG BASE;10MG		N20364 003
				MAR 03, 1995
	+	EQ 5MG BASE;20MG		N20364 004
				MAR 03, 1995

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	CONSOLIDATED PHARM	**250MG**		**N62058 001**
AB		**500MG**		**N62058 002**

COMOX

AB	COPANOS	**250MG**		**N62058 001**
AB		**500MG**		**N62058 002**

POLYMOX

AB	APOTHECON	**250MG**		**N63099 001**
				MAR 20, 1992
AB		**500MG**		**N63099 002**
				MAR 20, 1992

TRIMOX

AB	APOTHECON	**250MG**		**N63099 001**
				MAR 20, 1992
AB		**500MG**		**N63099 002**
				MAR 20, 1992

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

AB	CONSOLIDATED PHARM	**125MG/5ML**		**N62059 001**
AB		**250MG/5ML**		**N62059 002**

AMOXICILLIN TRIHYDRATE

AB	COPANOS	**125MG/5ML**		**N62059 001**
AB		**250MG/5ML**		**N62059 002**

AMPHOTERICIN B

INJECTABLE; INJECTION
AMPHOTERICIN B

AP	GENSIA	50MG/VIAL	N64062 001		
			MAR 31, 1995		

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001		
AP		EQ 125MG BASE/VIAL	N62860 001		
			FEB 05, 1988		
AP		EQ 250MG BASE/VIAL	N61395 002		
AP		EQ 250MG BASE/VIAL	N62860 002		
			FEB 05, 1988		
AP		EQ 500MG BASE/VIAL	N61395 003		
AP		EQ 500MG BASE/VIAL	N62860 003		
			FEB 05, 1988		
AP		EQ 1GM BASE/VIAL	N61395 004		
AP		EQ 1GM BASE/VIAL	N62738 001		
			FEB 19, 1987		
AP		EQ 1GM BASE/VIAL	N62860 004		
			FEB 05, 1988		
AP		EQ 2GM BASE/VIAL	N61395 005		
AP		EQ 2GM BASE/VIAL	N62738 002		
			FEB 19, 1987		
AP		EQ 2GM BASE/VIAL	N62860 005		
			FEB 05, 1988		
AP +		EQ 10GM BASE/VIAL	N61395 006		
@	CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	N61936 005		
@		EQ 250MG BASE/VIAL	N61936 001		
@		EQ 500MG BASE/VIAL	N61936 002		
@		EQ 1GM BASE/VIAL	N61936 003		
@		EQ 2GM BASE/VIAL	N61936 004		
@	COPANOS	EQ 125MG BASE/VIAL	N61936 005		
@		EQ 250MG BASE/VIAL	N61936 001		
@		EQ 500MG BASE/VIAL	N61936 002	> DLT >	
@		EQ 1GM BASE/VIAL	N61936 003	> DLT >	
@		EQ 2GM BASE/VIAL	N61936 004	> DLT >	
	PRINCIPEN			> DLT >	
AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001	> ADD >	
AP		EQ 125MG BASE/VIAL	N62860 001	> ADD >	
			FEB 05, 1988	> ADD >	
AP		EQ 250MG BASE/VIAL	N61395 002		
AP		EQ 250MG BASE/VIAL	N62860 002		
			FEB 05, 1988		

AMPICILLIN SODIUM

INJECTABLE; INJECTION
PRINCIPEN

AP	APOTHECON	EQ 500MG BASE/VIAL	N61395 003	
AP		EQ 500MG BASE/VIAL	N62860 003	
			FEB 05, 1988	
AP		EQ 1GM BASE/VIAL	N61395 004	
AP		EQ 1GM BASE/VIAL	N62738 001	
			FEB 19, 1987	
AP		EQ 1GM BASE/VIAL	N62860 004	
			FEB 05, 1988	
AP		EQ 2GM BASE/VIAL	N61395 005	
AP		EQ 2GM BASE/VIAL	N62738 002	
			FEB 19, 1987	
AP		EQ 2GM BASE/VIAL	N62860 005	
			FEB 05, 1988	
AP +		EQ 10GM BASE/VIAL	N61395 006	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL
AMPICILLIN TRIHYDRATE

AB	BIOCHEMIE	EQ 250MG BASE	N64082 001	
			AUG 29, 1995	
AB		EQ 500MG BASE	N64082 002	
			AUG 29, 1995	
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	
AB	COPANOS	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	

POWDER FOR RECONSTITUTION; ORAL
AMPICILLIN TRIHYDRATE

AB	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
AB	COPANOS	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
	POLYCILLIN			
AB +	BRISTOL	EQ 125MG BASE/5ML	N50308 001	
AB +		EQ 250MG BASE/5ML	N50308 002	
+		EQ 500MG BASE/5ML	N50308 003	
@		EQ 125MG BASE/5ML	N50308 001	
@		EQ 250MG BASE/5ML	N50308 002	
@		EQ 500MG BASE/5ML	N50308 003	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	VASOCON-A			
+	CIBA VISION	0.5%;0.05%	N18746 001	APR 30, 1990

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE			
AB	WATSON LABS	325MG;50MG;40MG;30MG	N74359 001	AUG 31, 1995
	FIORINAL W/CODEINE NO 3			
AB +	SANDOZ	325MG;50MG;40MG;30MG	N19429 003	OCT 26, 1990

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL AND ASPIRIN			
AB	STEVENS J	325MG;400MG	N81145 001	JAN 31, 1995

ATENOLOL

TABLET; ORAL

	ATENOLOL			
AB	COPLEY PHARM	50MG	N74120 001	FEB 24, 1995 > ADD >
AB		100MG	N74120 002	FEB 24, 1995 > ADD >
AB	LEMMON	50MG	N74056 001	JAN 18, 1995 > ADD >
AB		100MG	N74056 002	JAN 18, 1995
AB	MARTEC	50MG	N74127 001	FEB 21, 1995
AB		100MG	N74127 002	FEB 21, 1995

ATOVAQUONE

SUSPENSION; ORAL

	MEPRON			
+	BURROUGHS WELLCOME	750MG/5ML	N20500 001	FEB 08, 1995

ATROPINE

INJECTABLE; INJECTION

	ATROPEN			
AP	+ SURVIVAL TECH	**EQ 2MG SULFATE/0.7ML**	**N17106 001**	
	+	EQ 2MG SULFATE/0.7ML	N17106 001	
	ATROPINE			
AP	KALI DUPHAR	**EQ 2MG SULFATE/0.7ML**	**N71295 001**	JAN 30, 1987
	@ SOLVAY	EQ 2MG SULFATE/0.7ML	N71295 001	JAN 30, 1987

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

	AZATHIOPRINE SODIUM			
AP	BEDFORD	**EQ 100MG BASE/VIAL**	**N74419 001**	MAR 31, 1995
	IMURAN			
AP	+ BURROUGHS WELLCOME	**EQ 100MG BASE/VIAL**	**N17391 001**	

AZELAIC ACID

CREAM; TOPICAL

	AZELEX			
+	ALLERGAN	20%	N20428 001	SEP 13, 1995

BACITRACIN

INJECTABLE; INJECTION

	BACITRACIN			
AP	+ PFIZER	**50,000 UNITS/VIAL**	**N60282 001**	
	@	50,000 UNITS/VIAL	N60282 001	
AP	UPJOHN	**50,000 UNITS/VIAL**	**N60733 002**	
	+	50,000 UNITS/VIAL	N60733 002	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		BACITRACIN ZINC AND POLYMYXIN B SULFATE		
AT		ADV REMEDIES	500 UNITS/GM; 10,000 UNITS/GM	N64028 001 JAN 30, 1995
AT		BAUSCH AND LOMB	500 UNITS/GM; 10,000 UNITS/GM	N64046 001 JAN 26, 1995
		POLYSPORIN		
AT	+	BURROUGHS WELLCOME	500 UNITS/GM; 10,000 UNITS/GM	N61229 001

BENDROFLUMETHIAZIDE

TABLET; ORAL

		NATURETIN-10		
	+	APOTHECON	10MG	N12164 003
	+	SQUIBB	10MG	N12164 003
		NATURETIN-2.5		
	@	APOTHECON	2.5MG	N12164 001
	@	SQUIBB	2.5MG	N12164 001
		NATURETIN-5		
		APOTHECON	5MG	N12164 002
		SQUIBB	5MG	N12164 002

BENTONITE; SULFUR

POWDER; TOPICAL

		BENSULFOID		
	@	POYTHRESS	66.64%;33.32%	N02918 001

BETAMETHASONE BENZOATE

GEL; TOPICAL

> DLT >		UTICORT		
> DLT >	+	PARKE DAVIS	0.025%	N17244 001
> DLT >	@		0.025%	N17244 001
> ADD >				

LOTION; TOPICAL

> DLT >		UTICORT		
> DLT >	+	PARKE DAVIS	0.025%	N17528 001
> DLT >	@		0.025%	N17528 001
> ADD >				

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL

		BETAMETHASONE DIPROPIONATE		
AB		NMC	EQ 0.05% BASE	N74304 001 AUG 31, 1995
		DIPROLENE		
AB	+	SCHERING	EQ 0.05% BASE	N18741 001 JUL 27, 1983

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

		BRETYLOL		
AP		DUPONT MERCK	50MG/ML	N17954 001
AP		FAULDING	50MG/ML	N17954 001

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

		DIMETANE-DC		
AA		ROBINS AH	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006 MAR 29, 1984
AA	+		2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006 MAR 29, 1984

BUMETANIDE

INJECTABLE; INJECTION

		BUMETANIDE		
AP		BEDFORD	0.25MG/ML	N74441 001 JAN 27, 1995

TABLET; ORAL

		BUMETANIDE		
AB		ZENITH LABS	0.5MG	N74225 001 APR 24, 1995
AB			1MG	N74225 002 APR 24, 1995
AB			2MG	N74225 003 APR 24, 1995
		BUMEX		
AB		ROCHE	0.5MG	N18225 002 FEB 28, 1983

BUMETANIDE

TABLET; ORAL

		BUMEX		
AB		ROCHE	1MG	N18225 001 FEB 28, 1983
AB	+		2MG	N18225 003 JUN 14, 1985

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

		MARCAINE HCL		
AP	+	SANOFI WINTHROP	0.25%	N16964 001
AP	+		0.5%	N16964 006
AP	+		0.75%	N16964 009
AP	+	STERLING WINTHROP	0.25%	N16964 001
AP	+		0.5%	N16964 006
AP	+		0.75%	N16964 009
> ADD >		**MARCAINE HCL PRESERVATIVE FREE**		
> ADD > AP	+	SANOFI WINTHROP	0.5%	N16964 005

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

		MARCAINE HCL W/ EPINEPHRINE		
AP	+	SANOFI WINTHROP	0.25%;0.0091MG/ML	N16964 004
AP	+		0.5%;0.0091MG/ML	N16964 008
AP	+		0.75%;0.0091MG/ML	N16964 010
AP	+	STERLING WINTHROP	0.25%;0.0091MG/ML	N16964 004
AP	+		0.5%;0.0091MG/ML	N16964 008
AP	+		0.75%;0.0091MG/ML	N16964 010

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

		CAFERGOT		
AA	+	SANDOZ	100MG;1MG	N06620 001
	@		100MG;1MG	N06620 001
		ERCATAB		
AA		GENEVA PHARMS	100MG;1MG	N84294 001
AA	+		100MG;1MG	N84294 001

CALCITONIN, SALMON

INJECTABLE; INJECTION

		CALCITONIN-SALMON		
AP		ASTRA	200 IU/ML	N73690 001 APR 14, 1995

SPRAY, METERED; NASAL

		MIACALCIN		
	+	SANDOZ	200 IU/INH	N20313 002 AUG 17, 1995

CAPTOPRIL

TABLET; ORAL

		CAPOTEN		
AB		BRISTOL MYERS SQUIBB	12.5MG	N18343 005 JAN 17, 1985
AB			25MG	N18343 002
AB			50MG	N18343 001
AB	+		100MG	N18343 003
		CAPTOPRIL		
AB		APOTHECON	12.5MG	N74472 001 MAR 31, 1995
AB			25MG	N74472 002 MAR 31, 1995
AB			50MG	N74472 003 MAR 31, 1995
AB			100MG	N74472 004 MAR 31, 1995

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

		CAPOZIDE 25/25		
		SQUIBB	25MG;25MG	N18709 002 OCT 12, 1984
	+		25MG;25MG	N18709 002 OCT 12, 1984
		CAPOZIDE 50/15		
		SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984
	+		50MG;15MG	N18709 004 OCT 12, 1984
		CAPOZIDE 50/25		
	+	SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	CAPOZIDE 50/25			
	SQUIBB	50MG;25MG		N18709 003
				OCT 12, 1984

CARBACHOL

SOLUTION; INTRAOCULAR

	CARBASTAT		
AT	CIBA	0.01%	**N73677 001**
			APR 28, 1995
	MIOSTAT		**N16968 001**
AT +	ALCON	0.01%	

CARBIDOPA; LEVODOPA

TABLET; ORAL

	CARBIDOPA AND LEVODOPA		
AB	GENEVA PHARMS	10MG;100MG	**N73586 001**
			JUN 29, 1995
AB		25MG;100MG	**N73587 001**
			JUN 29, 1995
AB		25MG;250MG	**N73620 001**
			JUN 29, 1995

> ADD > CARVEDILOL

> ADD > TABLET; ORAL

> ADD >	COREG		
> ADD >	SMITHKLINE BEECHAM	6.25MG	N20297 003
			SEP 14, 1995
> ADD >		12.5MG	N20297 002
			SEP 14, 1995
> ADD >		25MG	N20297 001
			SEP 14, 1995
> ADD > +			

CEFACLOR

CAPSULE; ORAL

	CECLOR		
AB +	LILLY	EQ 250MG BASE	**N50521 001**
AB		EQ 250MG BASE	**N62205 001**
AB +		EQ 500MG BASE	**N50521 002**

CEFACLOR

CAPSULE; ORAL

	CECLOR		
AB	LILLY	EQ 500MG BASE	**N62205 002**
	CEFACLOR		
AB	LEDERLE	EQ 250MG BASE	**N64107 001**
			APR 27, 1995
AB		EQ 500MG BASE	**N64107 002**
			APR 27, 1995
AB	ZENITH LABS	EQ 250MG BASE	**N64061 001**
			APR 27, 1995
AB		EQ 500MG BASE	**N64061 002**
			APR 27, 1995

POWDER FOR RECONSTITUTION; ORAL

	CECLOR		
AB +	LILLY	EQ 125MG BASE/5ML	**N50522 001**
AB		EQ 125MG BASE/5ML	**N62206 001**
AB		EQ 187MG BASE/5ML	**N62206 003**
AB +			APR 20, 1988
AB +		EQ 250MG BASE/5ML	**N50522 002**
AB		EQ 250MG BASE/5ML	**N62206 002**
AB		EQ 375MG BASE/5ML	**N62206 004**
AB +			APR 20, 1988
	CEFACLOR		
AB	LEDERLE	EQ 125MG BASE/5ML	**N64114 001**
			APR 28, 1995
AB		EQ 187MG BASE/5ML	**N64115 001**
			APR 28, 1995
AB		EQ 250MG BASE/5ML	**N64116 001**
			APR 28, 1995
AB		EQ 375MG BASE/5ML	**N64110 001**
			APR 28, 1995
AB	ZENITH LABS	EQ 125MG BASE/5ML	**N64087 001**
			APR 28, 1995
AB		EQ 187MG BASE/5ML	**N64086 001**
			APR 28, 1995
AB		EQ 250MG BASE/5ML	**N64085 001**
			APR 28, 1995
AB		EQ 375MG BASE/5ML	**N64070 001**
			APR 28, 1995

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

	MANDOL		
+	LILLY	EQ 500MG BASE/VIAL	N50504 001

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION
MANDOL
@ LILLY — EQ 500MG BASE/VIAL — N50504 001

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	APOTHECON	EQ 500MG BASE/VIAL	N62831 001 DEC 09, 1988
AP		EQ 1GM BASE/VIAL	N62831 002 DEC 09, 1988
AP		EQ 10GM BASE/VIAL	N62831 003 SEP 25, 1992
AP	ELKINS SINN	EQ 250MG BASE/VIAL	N62807 001 JAN 12, 1988
AP		EQ 500MG BASE/VIAL	N62807 002 JAN 12, 1988
AP		EQ 1GM BASE/VIAL	N62807 003 JAN 12, 1988
AP		EQ 5GM BASE/VIAL	N62807 004 JAN 12, 1988
AP		EQ 10GM BASE/VIAL	N62807 005 JAN 12, 1988
AP		EQ 20GM BASE/VIAL	N62807 006 JAN 12, 1988
	@	EQ 250MG BASE/VIAL	N62807 001 JAN 12, 1988
	@	EQ 500MG BASE/VIAL	N62807 002 JAN 12, 1988
	@	EQ 1GM BASE/VIAL	N62807 003 JAN 12, 1988
	@	EQ 5GM BASE/VIAL	N62807 004 JAN 12, 1988
	@	EQ 10GM BASE/VIAL	N62807 005 JAN 12, 1988
	@	EQ 20GM BASE/VIAL	N62807 006 JAN 12, 1988

ZOLICEF

AP	APOTHECON	EQ 500MG BASE/VIAL	N62831 001 DEC 09, 1988
AP		EQ 1GM BASE/VIAL	N62831 002 DEC 09, 1988
AP		EQ 10GM BASE/VIAL	N62831 003 SEP 25, 1992

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID
PFIZER — EQ 1GM BASE/VIAL — N63333 001 MAR 31, 1995
EQ 2GM BASE/VIAL — N63333 002 MAR 31, 1995

CEFORANIDE

INJECTABLE; INJECTION
PRECEF

APOTHECON	500MG/VIAL	N62579 001 NOV 26, 1984
	1GM/VIAL	N62579 002 NOV 26, 1984
	2GM/VIAL	N62579 003 NOV 26, 1984
	10GM/VIAL	N62579 004 NOV 26, 1984
	20GM/VIAL	N62579 005 NOV 26, 1984
BRISTOL	500MG/VIAL	N62579 001 NOV 26, 1984
	1GM/VIAL	N62579 002 NOV 26, 1984
	2GM/VIAL	N62579 003 NOV 26, 1984
	10GM/VIAL	N62579 004 NOV 26, 1984
	20GM/VIAL	N62579 005 NOV 26, 1984

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	MERCK SHARP DOHME	EQ 20MG BASE/ML	N50581 002 SEP 20, 1984
+		EQ 40MG BASE/ML	N50581 001 SEP 20, 1984
	@	EQ 20MG BASE/ML	N50581 002 SEP 20, 1984
	@	EQ 40MG BASE/ML	N50581 001 SEP 20, 1984

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

		ROCEPHIN			
AP	+	ROCHE	EQ 250MG BASE/VIAL	N50585 001	
				DEC 21, 1984	
AP	+		EQ 500MG BASE/VIAL	N50585 002	
				DEC 21, 1984	
AP	+		EQ 1GM BASE/VIAL	N50585 003	
				DEC 21, 1984	
	+		EQ 250MG BASE/VIAL	N50585 001	
				DEC 21, 1984	
	+		EQ 500MG BASE/VIAL	N50585 002	
				DEC 21, 1984	
	+		EQ 1GM BASE/VIAL	N50585 003	
				DEC 21, 1984	

CEFUROXIME SODIUM

INJECTABLE; INJECTION

		KEFUROX			
AP	+	LILLY	EQ 7.5GM BASE/VIAL	N62591 003	
				DEC 17, 1987	
AP			EQ 7.5GM BASE/VIAL	N62591 003	
				DEC 17, 1987	
		ZINACEF			
AP		GLAXO	EQ 7.5GM BASE/VIAL	N50558 004	
				OCT 23, 1986	
AP	+		EQ 7.5GM BASE/VIAL	N50558 004	
				OCT 23, 1986	

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

		CEPHALEXIN				
AB		APOTHECON	EQ 125MG BASE/5ML	N62986 001		
				APR 18, 1991		
AB			EQ 250MG BASE/5ML	N62987 001	>_DLT_>	
				JUL 25, 1989	>_DLT_>	
AB		SQUIBB MARK	EQ 125MG BASE/5ML	N62986 001	>_DLT_>	
				APR 18, 1991	>_ADD_>	
AB			EQ 250MG BASE/5ML	N62987 001	>_ADD_>	
				JUL 25, 1989		

CEPHRADINE

CAPSULE; ORAL

		VELOSEF		
AB	+	APOTHECON	250MG	N61764 001
AB	+		500MG	N61764 002
AB	+	ERSANA	250MG	N61764 001
AB	+		500MG	N61764 002

INJECTABLE; INJECTION

		VELOSEF		
	+	APOTHECON	250MG/VIAL	N61976 001
	+		500MG/VIAL	N61976 002
	+		1GM/VIAL	N61976 004
	+		2GM/VIAL	N61976 003
	+		4GM/VIAL	N61976 005
	+	SQUIBB	250MG/VIAL	N61976 001
	+		500MG/VIAL	N61976 002
	+		1GM/VIAL	N61976 004
	+		2GM/VIAL	N61976 003
	+		4GM/VIAL	N61976 005

POWDER FOR RECONSTITUTION; ORAL

		VELOSEF '125'		
AB	+	APOTHECON	125MG/5ML	N61763 001
AB	+	ERSANA	125MG/5ML	N61763 001
		VELOSEF '250'		
AB	+	APOTHECON	250MG/5ML	N61763 002
AB	+	ERSANA	250MG/5ML	N61763 002

CHLORAMPHENICOL

CAPSULE; ORAL

		MYCHEL		
AB		ARMENPHARM	250MG	N60851 001
AB		RACHELLE	250MG	N60851 001

SOLUTION/DROPS; OPHTHALMIC

		OPTOMYCIN		
AT		OPTOPICS	0.5%	N62171 001
				MAR 31, 1982
		@	0.5%	N62171 001
				MAR 31, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

> DLT >		**CHLORAMPHENICOL**			
> DLT >	**AP**	ELKINS SINN	**EQ 1GM BASE/VIAL**	**N62406 001**	
> DLT >				NOV 09, 1982	
> ADD >		@	EQ 1GM BASE/VIAL	N62406 001	
> ADD >				NOV 09, 1982	

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

	MENRIUM 10-4			
	ROCHE	10MG;0.4MG	N14740 006	
	@	10MG;0.4MG	N14740 006	
	MENRIUM 5-2			
	ROCHE	5MG;0.2MG	N14740 002	
	@	5MG;0.2MG	N14740 002	
	MENRIUM 5-4			
+	ROCHE	5MG;0.4MG	N14740 004	
	@	5MG;0.4MG	N14740 004	

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

	CHLORPHENIRAMINE MALEATE			
AP	STERIS	**10MG/ML**	**N83593 001**	
		100MG/ML	N86095 001	
	@	10MG/ML	N83593 001	
	@	100MG/ML	N86095 001	

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CHLORPROMAZINE HCL			
AP	STERIS	**25MG/ML**	**N85591 001**	
	@	25MG/ML	N85591 001	

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE			
AB	LEMMON	**100MG**	**N88768 001**	
			OCT 11, 1984	

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE			
	@ LEMMON	100MG	N88768 001	
			OCT 11, 1984	
	GLUCAMIDE			
AB	LEMMON	**250MG**	**N88641 001**	
			OCT 11, 1984	
	@	250MG	N88641 001	
			OCT 11, 1984	

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	MUTUAL PHARM	**25MG**	**N89738 001**	
			SEP 19, 1988	
AB		**50MG**	**N89739 001**	
			SEP 19, 1988	
	@	25MG	N89738 001	
			SEP 19, 1988	
	@	50MG	N89739 001	
			SEP 19, 1988	

CHLORZOXAZONE

TABLET; ORAL

		CHLORZOXAZONE			
> ADD >	**AA**	AMIDE PHARM	**500MG**	**N40113 001**	
> ADD >				SEP 29, 1995	

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

	CHOLYBAR			
+	PARKE DAVIS	EQ 4GM RESIN/BAR	N71621 001	
			MAY 26, 1988	
		EQ 4GM RESIN/BAR	N71739 001	
			MAY 26, 1988	
	@	EQ 4GM RESIN/BAR	N71621 001	
			MAY 26, 1988	
	@	EQ 4GM RESIN/BAR	N71739 001	
			MAY 26, 1988	

CHOLESTYRAMINE

TABLET; ORAL
QUESTRAN
+ BRISTOL MYERS SQUIBB EQ 1GM RESIN N73403 001 APR 28, 1994
@ EQ 1GM RESIN N73403 001 APR 28, 1994

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	BAKER NORTON	200MG	N74424 001 JUL 28, 1995	
AB		300MG	N74424 002 JUL 28, 1995	
AB		400MG	N74424 003 JUL 28, 1995	
AB		800MG	N74424 004 JUL 28, 1995	
AB	GENEVA PHARMS	200MG	N74100 001 JAN 31, 1995	
AB		300MG	N74100 002 JAN 31, 1995	
AB		400MG	N74100 003 JAN 31, 1995	
AB		800MG	N74100 004 JAN 31, 1995	
AB	LEK LJUBLJANA	200MG	N74250 001 JUN 29, 1995	
AB		300MG	N74250 002 JUN 29, 1995	> ADD >
AB		400MG	N74250 003 JUN 29, 1995	> ADD >
AB		800MG	N74250 004 JUN 29, 1995	> ADD >
AB	LEMMON	200MG	N74365 001 FEB 28, 1995	
AB		300MG	N74365 002 FEB 28, 1995	
AB		400MG	N74365 003 FEB 28, 1995	
AB		800MG	N74365 004 FEB 28, 1995	
AB	MOVA	300MG	N74340 001 JUN 23, 1995	

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	MOVA	400MG	N74340 002 JUN 23, 1995
AB		800MG	N74339 001 JUN 23, 1995
AB	ZENITH LABS	200MG	N74401 001 MAY 30, 1995
AB		300MG	N74401 002 MAY 30, 1995
AB		400MG	N74401 003 MAY 30, 1995
AB		800MG	N74402 001 MAY 30, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	ABBOTT	EQ 300MG BASE/2ML	N74344 001 JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74345 001 JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74422 001 JAN 31, 1995

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL
PROPULSID
+ JANSSEN EQ 1MG BASE/ML N20398 001 SEP 15, 1995

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLEOCIN
UPJOHN EQ 1% BASE N50537 002 FEB 22, 1994

SWAB; TOPICAL
CLEOCIN
UPJOHN EQ 1% BASE N50537 002 FEB 22, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL
TEMOVATE E

BX	+ GLAXO	0.05%	N20340 001 JUN 17, 1994		

TEMOVATE EMOLLIENT

BX	+ GLAXO	0.05%	N20340 001 JUN 17, 1994		

OINTMENT; TOPICAL
EMBELINE

AB	DPT	0.05%	N74221 001 MAR 31, 1995	> ADD > > DLT >	

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE

AB	GENEVA PHARMS	500MG	N72191 001 MAY 02, 1988	> DLT > > DLT >	
	@	500MG	N72191 001 MAY 02, 1988	> DLT > > DLT > > ADD > > ADD > > ADD > > ADD >	

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL

	BASEL PHARMS	50MG	N19906 002 DEC 29, 1989		
	+	75MG	N19906 003 DEC 29, 1989	> DLT > > DLT >	
	+	50MG	N19906 002 DEC 29, 1989	> DLT > > ADD >	
		75MG	N19906 003 DEC 29, 1989		

CLOTRIMAZOLE

SOLUTION; TOPICAL
CLOTRIMAZOLE

AT	LEMMON	1%	N73306 001 FEB 28, 1995		

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXACILLIN SODIUM

AB	+ APOTHECON	EQ 250MG BASE	N61452 001		
AB	+	EQ 500MG BASE	N61452 002		

TEGOPEN

AB	+ APOTHECON	EQ 250MG BASE	N61452 001		
AB	+	EQ 500MG BASE	N61452 002		

POWDER FOR RECONSTITUTION; ORAL
TEGOPEN

	@ APOTHECON	EQ 125MG BASE/5ML	N50192 001		
AA	BRISTOL	EQ 125MG BASE/5ML	N50192 001		

CLOZAPINE

TABLET; ORAL
CLOZARIL

	SANDOZ	25MG	N19758 001 SEP 26, 1989		
	+	100MG	N19758 002 SEP 26, 1989		
	+	25MG	N19758 001 SEP 26, 1989		
		100MG	N19758 002 SEP 26, 1989		

COLISTIN SULFATE

SUSPENSION; ORAL
COLY-MYCIN S

	PARKE DAVIS	EQ 25MG BASE/5ML	N50355 001		
	@	EQ 25MG BASE/5ML	N50355 001		

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH

AP	PARKE DAVIS	40 UNITS/VIAL	N08317 004		
	@	40 UNITS/VIAL	N08317 004		

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

	CROLOM			
AT	BAUSCH AND LOMB	4%	N74443 001	JAN 30, 1995
	OPTICROM			
AT +	FISONS	4%	N18155 001	OCT 03, 1984

CUPRIC SULFATE

INJECTABLE; INJECTION

	CUPRIC SULFATE			
+	FUJISAWA	EQ 0.4MG COPPER/ML	N19350 001	MAY 05, 1987
@		EQ 0.4MG COPPER/ML	N19350 001	MAY 05, 1987

CYANOCOBALAMIN

INJECTABLE; INJECTION

	CYANOCOBALAMIN			
AP	AKORN	1MG/ML	N87969 001	NOV 10, 1983
@		1MG/ML	N87969 001	NOV 10, 1983
@	WARNER CHILCOTT	1MG/ML	N07085 002	
	RUBRAMIN PC			
AP +	SQUIBB	0.1MG/ML	N06799 002	
@		0.1MG/ML	N06799 002	
	SYTOBEX			
AP	PARKE DAVIS	1MG/ML	N07085 002	

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

	CYCLOBENZAPRINE HCL			
AB	BARR	10MG	N73541 001	MAY 23, 1995
> ADD > AB	SIDMAK LABS NJ	10MG	N74421 001	SEP 29, 1995
> ADD >				

CYCLOSPORINE

CAPSULE; ORAL

	NEORAL					
> ADD >	BP	SANDOZ	25MG	N50715 001	JUL 14, 1995	
> ADD >			50MG	N50715 003	JUL 14, 1995	
> ADD >	BP					
> ADD >			100MG	N50715 002	JUL 14, 1995	
> ADD >	BP +					
> ADD >			25MG	N50715 001	JUL 14, 1995	
> DLT >						
> DLT >			50MG	N50715 003	JUL 14, 1995	
> DLT >						
> DLT >			100MG	N50715 002	JUL 14, 1995	
> DLT >	+					
> DLT >						
	SANDIMMUNE					
> ADD >	BP	SANDOZ	25MG	N50625 001	MAR 02, 1990	
> ADD >			50MG	N50625 003	NOV 23, 1992	
> ADD >	BP					
> ADD >			100MG	N50625 002	MAR 02, 1990	
> ADD >	BP +					
> ADD >			25MG	N50625 001	MAR 02, 1990	
> DLT >						
> DLT >			50MG	N50625 003	NOV 23, 1992	
> DLT >						
> DLT >			100MG	N50625 002	MAR 02, 1990	
> DLT >	+					
> DLT >						

SOLUTION; ORAL

	NEORAL				
> ADD >	BP +	SANDOZ	100MG/ML	N50716 001	JUL 14, 1995
> ADD >			100MG/ML	N50716 001	JUL 14, 1995
> DLT >	+				
> DLT >					
	SANDIMMUNE				
> ADD >	BP +	SANDOZ	100MG/ML	N50574 001	NOV 14, 1983
> ADD >			100MG/ML	N50574 001	NOV 14, 1983
> DLT >	+				
> DLT >					

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

	CYPROHEPTADINE HCL			
AA	ASCOT	4MG	N87685 001	OCT 25, 1982

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL
@ ASCOT 4MG N87685 001 OCT 25, 1982

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL
AP CETUS BEN VENUE **EQ 20MG BASE/VIAL** **N64103 001** FEB 03, 1995

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DDAVP
\+ RHONE POULENC 0.015MG/ML N18938 002 APR 25, 1995

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE
\+ RHONE POULENC RORER 0.15MG/INH N20355 001 MAR 07, 1994

STIMATE
\+ RHONE POULENC RORER 0.15MG/INH N20355 001 MAR 07, 1994

> ADD > TABLET; ORAL
> ADD > DDAVP
> ADD > RHONE POULENC RORER 0.1MG N19955 001 SEP 06, 1995
> ADD > \+ 0.2MG N19955 002 SEP 06, 1995

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGEN
AB \+ ORGANON **0.15MG;0.03MG** **N20071 001** DEC 10, 1992
@ 0.15MG;0.03MG N20071 001 DEC 10, 1992

ORTHO-CEPT
AB JOHNSON RW **0.15MG;0.03MG** **N20301 001** DEC 14, 1992

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
ORTHO-CEPT
JOHNSON RW 0.15MG;0.03MG N20301 001 DEC 14, 1992

DEXAMETHASONE

AEROSOL; TOPICAL
DECASPRAY
\+ MERCK SHARP DOHME 0.4% N12731 002
\+ 0.04% N12731 002

TABLET; ORAL
HEXADROL
BP ORGANON 0.5MG N12675 004
BP 0.75MG N12675 007
BP 1.5MG N12675 009
@ 0.5MG N12675 004
@ 0.75MG N12675 007
@ 1.5MG N12675 009

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
DEXASPORIN
> ADD > **AT** BAUSCH AND LOMB **0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** **N64135 001** SEP 13, 1995

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE
AP FUJISAWA **EQ 4MG PHOSPHATE/ML** **N88448 001** JAN 25, 1984
@ EQ 4MG PHOSPHATE/ML N88448 001 JAN 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE
AP AKORN **EQ 4MG PHOSPHATE/ML** **N84493 001**
@ EQ 4MG PHOSPHATE/ML N84493 001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
ZINECARD
+ PHARMACIA — EQ 250MG BASE/VIAL — N20212 001 — MAY 26, 1995
+ — EQ 500MG BASE/VIAL — N20212 002 — MAY 26, 1995

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 2.5% IN PLASTIC CONTAINER
MCGAW — 2.5GM/100ML — N19626 001 — FEB 02, 1988
@ — 2.5GM/100ML — N19626 001 — FEB 02, 1988

DEXTROSE 5% IN PLASTIC CONTAINER
>ADD< **AP** DHL — **5GM/100ML** — **N19971 001** — SEP 28, 1995

DEXTROSE 7.7% IN PLASTIC CONTAINER
MCGAW — 7.7GM/100ML — N19626 003 — FEB 02, 1988
@ — 7.7GM/100ML — N19626 003 — FEB 02, 1988

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM
AP FUJISAWA — **5MG/ML** — **N70662 001** — JUN 25, 1986
@ — 5MG/ML — N70662 001 — JUN 25, 1986

DICLOFENAC POTASSIUM

TABLET; ORAL
CATAFLAM
GEIGY — 25MG — N20142 001 — NOV 24, 1993
@ — 25MG — N20142 001 — NOV 24, 1993

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM
>ADD< **AB** GENEVA PHARMS — **25MG** — **N74376 001** — SEP 28, 1995
>ADD< **AB** — **50MG** — **N74376 002** — SEP 28, 1995
AB ROXANE — **25MG** — **N74391 001** — JUN 29, 1995
AB — **50MG** — **N74391 002** — JUN 29, 1995
AB — **75MG** — **N74391 003** — JUN 29, 1995

VOLTAREN
AB + GEIGY — **25MG** — **N19201 001** — JUL 28, 1988
AB + — **50MG** — **N19201 002** — JUL 28, 1988
AB + — **75MG** — **N19201 003** — JUL 28, 1988

DICLOXACILLIN SODIUM

CAPSULE; ORAL
DICLOXACILLIN SODIUM
AB APOTHECON — **EQ 250MG BASE** — **N61454 001**
AB — **EQ 500MG BASE** — **N61454 003**
EQ 125MG BASE — N61454 002

DYNAPEN
AB APOTHECON — **EQ 250MG BASE** — **N61454 001**
AB — **EQ 500MG BASE** — **N61454 003**
EQ 125MG BASE — N61454 002

POWDER FOR RECONSTITUTION; ORAL
DICLOXACILLIN SODIUM
AB APOTHECON — **EQ 62.5MG BASE/5ML** — **N61455 001**
DYNAPEN
AB APOTHECON — **EQ 62.5MG BASE/5ML** — **N61455 001**
>ADD< @ — EQ 62.5MG BASE/5ML — N50337 002
>DLT< @ BRISTOL — EQ 62.5MG BASE/5ML — N50337 002

DIDANOSINE

POWDER FOR RECONSTITUTION; ORAL
VIDEX
BRISTOL MYERS SQUIBB — 250MG/PACKET — N20155 005 — OCT 09, 1991

DIDANOSINE

POWDER FOR RECONSTITUTION; ORAL

	VIDEX			
	+ BRISTOL MYERS SQUIBB	375MG/PACKET	N20155 006	OCT 09, 1991
	+	250MG/PACKET	N20155 005	OCT 09, 1991
	@	375MG/PACKET	N20155 006	OCT 09, 1991

DIENESTROL

CREAM; VAGINAL

	DIENESTROL			
> DLT > AT	+ JOHNSON RW	0.01%	N06110 005	
> ADD >	+	0.01%	N06110 005	
> DLT >	DV			
> ADD >	@ HOECHST MARION RSSL	0.01%	N83518 001	
> DLT > AT	MERRELL DOW	0.01%	N83518 001	

DIFLORASONE DIACETATE

CREAM; TOPICAL

	DIFLORASONE DIACETATE			
> DLT >	@ UPJOHN	0.05%	N19259 001	AUG 28, 1985
> DLT >				
> DLT >				
> ADD >	FLORONE E			
> ADD > BX	+ UPJOHN	0.05%	N19259 001	AUG 28, 1985
> ADD >				
	PSORCON			
BX	DERMIK	0.05%	N20205 001	NOV 20, 1992
BX	+	0.05%	N20205 001	NOV 20, 1992

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

	CARDIZEM			
	+ HOECHST MARION RSSL	25MG/VIAL	N20027 003	AUG 18, 1995

TABLET; ORAL

	DILTIAZEM HCL			
AB	LEMMON	30MG	N74185 001	MAY 31, 1995

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

	DILTIAZEM HCL			
AB	LEMMON	60MG	N74185 002	MAY 31, 1995
AB		90MG	N74185 003	MAY 31, 1995
AB		120MG	N74185 004	MAY 31, 1995
AB	ZENITH LABS	30MG	N74168 001	MAR 03, 1995
AB		60MG	N74168 002	MAR 03, 1995
AB		90MG	N74168 003	MAR 03, 1995
AB		120MG	N74168 004	MAR 03, 1995

DIMENHYDRINATE

INJECTABLE; INJECTION

	DIMENHYDRINATE			
AP	STERIS	50MG/ML	N83531 001	
	@	50MG/ML	N83531 001	

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL

	CERVIDIL			
	+ CONTROLLED THERAP	10MG	N20411 001	MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIPHENHYDRAMINE HCL			
AA	WEST WARD PHARM	50MG	N83567 001	
	@	50MG	N83567 001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AKPRO			
> ADD > AT	AKORN	0.1%	N74382 001	SEP 29, 1995
> ADD >				
> ADD >				

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	DIPIVEFRIN HCL			
AT	BAUSCH AND LOMB	**0.1%**		**N74188 001**
				MAY 19, 1995

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

	DYNABAC		
+	LILLY	250MG	N50678 001
			JUN 19, 1995

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

	DEPAKOTE		
+	ABBOTT	EQ 125MG BASE	N19680 001
			SEP 12, 1989
+		EQ 125MG VALPROIC ACID	N19680 001
			SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL

	DEPAKOTE		
	ABBOTT	EQ 125MG BASE	N18723 003
			OCT 26, 1984
		EQ 250MG BASE	N18723 001
			MAR 10, 1983
		EQ 500MG BASE	N18723 002
			MAR 10, 1983
+		EQ 125MG VALPROIC ACID	N18723 003
			OCT 26, 1984
		EQ 250MG VALPROIC ACID	N18723 001
			MAR 10, 1983
		EQ 500MG VALPROIC ACID	N18723 002
			MAR 10, 1983
+			

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		DOBUTAMINE HCL			
AP		ASTRA	**EQ 12.5MG BASE/ML**	**N74098 001**	
				FEB 21, 1995	> DLT >
AP		SANOFI WINTHROP	**EQ 12.5MG BASE/ML**	**N74292 001**	> DLT >
				FEB 16, 1995	> DLT >
					> DLT >

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		DOPAMINE HCL IN DEXTROSE 5%		
AP	+	ABBOTT	**1.6MG/ML**	**N20542 001**
				AUG 30, 1995
		INTROPIN		
AP	+	DUPONT MERCK	**40MG/ML**	**N17395 001**
AP	+		**80MG/ML**	**N17395 002**
AP	+		**160MG/ML**	**N17395 003**
AP	+	FAULDING	**40MG/ML**	**N17395 001**
AP	+		**80MG/ML**	**N17395 002**
AP	+		**160MG/ML**	**N17395 003**

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		DOXORUBICIN HCL		
AP		GENSIA	**2MG/ML**	**N64140 001**
				JUL 28, 1995
AP			**200MG/100ML**	**N64140 002**
				JUL 28, 1995
AP		PHARMACHEMIE (NL)	**2MG/ML**	**N63336 001**
				FEB 28, 1995
AP			**200MG/100ML**	**N63336 004**
				FEB 28, 1995

DOXYCYCLINE

CAPSULE; ORAL

	DOXYCYCLINE MONOHYDRATE			
+	VINTAGE PHARMS	EQ 100MG BASE		N50641 001
				DEC 29, 1989
	MONODOX			
+	OCLASSEN	EQ 100MG BASE		N50641 001
				DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

		DOXYCYCLINE HYCLATE			
		HALSEY	**EQ 50MG BASE**	**N62119 002**	
				MAY 24, 1985	
			EQ 100MG BASE	**N62119 001**	
				MAY 24, 1985	

> DLT > **AB**

> DLT > **AB**

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

>ADD>		@ HALSEY	EQ 50MG BASE	N62119 002 MAY 24, 1985
>ADD>		@	EQ 100MG BASE	N62119 001 MAY 24, 1985
>ADD>				
>ADD>				
AB		PVT FORM	**EQ 50MG BASE**	**N62631 001 JUL 24, 1986**
AB			**EQ 100MG BASE**	**N62631 002 JUL 24, 1986**
	@		EQ 50MG BASE	N62631 001 JUL 24, 1986
	@		EQ 100MG BASE	N62631 002 JUL 24, 1986

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

AP	DUPONT MERCK	**2.5MG/ML**	**N71645 001 APR 07, 1988**
AP	FAULDING	**2.5MG/ML**	**N71645 001 APR 07, 1988**
AP	SANOFI WINTHROP	**2.5MG/ML**	**N72272 001 AUG 31, 1995**

EDETATE DISODIUM

INJECTABLE; INJECTION
SODIUM VERSENATE

	+ 3M	200MG/ML	N10573 001
	@	200MG/ML	N10573 001

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
VASERETIC
MERCK 5MG;12.5MG N19221 003 JUL 12, 1995

>ADD> EPOPROSTENOL SODIUM

>ADD> INJECTABLE; INJECTION
>ADD> FLOLAN

>ADD>	+ BURROUGHS WELLCOME	EQ 0.5MG BASE/VIAL	N20444 001 SEP 20, 1995
>ADD>	+	EQ 1.5MG BASE/VIAL	N20444 002 SEP 20, 1995

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC

AB		FAULDING	**250MG**	**N50536 001**
AB	+		**250MG**	**N50536 001**
AB	+	PARKE DAVIS	**250MG**	**N62338 001**
AB	+		**250MG**	**N62618 001 SEP 25, 1985**
	@		250MG	N62338 001
	@		250MG	N62618 001 SEP 25, 1985

TABLET, DELAYED RELEASE; ORAL
ROBINMYCIN

AB	ROBINS AH	**250MG**	**N61633 001**
	@	250MG	N61633 001

ERYTHROMYCIN ESTOLATE

DROPS; ORAL
ILOSONE

	+ DISTA	EQ 100MG BASE/ML	N61894 003

SUSPENSION/DROPS; ORAL
ILOSONE

	+ DISTA	EQ 100MG BASE/ML	N61894 003

ERYTHROMYCIN ETHYLSUCCINATE

DROPS; ORAL
PEDIAMYCIN

	+ ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002

SUSPENSION; ORAL
WYAMYCIN E

AB	WYETH AYERST	**EQ 200MG BASE/5ML**	**N62123 002**

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
WYAMYCIN E
AB WYETH AYERST EQ 400MG BASE/5ML N62123 001
@ EQ 200MG BASE/5ML N62123 002
@ EQ 400MG BASE/5ML N62123 001

SUSPENSION/DROPS; ORAL
PEDIAMYCIN
+ ROSS LABS EQ 100MG BASE/2.5ML N62305 002

ERYTHROMYCIN STEARATE

TABLET; ORAL
ETHRIL 250
AB SQUIBB EQ 250MG BASE N61605 001
@ EQ 250MG BASE N61605 001
ETHRIL 500
AB SQUIBB EQ 500MG BASE N61605 002
@ EQ 500MG BASE N61605 002

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA
BX 3M 0.05MG/24HR N20375 001 DEC 22, 1994
BX + 0.05MG/24HR N20375 001 DEC 22, 1994
BX 0.1MG/24HR N20375 002 DEC 22, 1994
BX + 0.1MG/24HR N20375 002 DEC 22, 1994
VIVELLE
BX 0.05MG/24HR N20323 002 OCT 28, 1994
BX 0.1MG/24HR N20323 004 OCT 28, 1994
0.0375MG/24HR N20323 001 OCT 28, 1994
0.075MG/24HR N20323 003 OCT 28, 1994
BX + CIBA GEIGY 0.05MG/24HR N20323 002 OCT 28, 1994
BX + 0.1MG/24HR N20323 004 OCT 28, 1994

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
VIVELLE
+ CIBA GEIGY 0.0375MG/24HR N20323 001 OCT 28, 1994
+ 0.075MG/24HR N20323 003 OCT 28, 1994

ESTRADIOL VALERATE

INJECTABLE; INJECTION
DELESTROGEN
+ NO FIRM 10MG/ML N09402 002
AO + SQUIBB 10MG/ML N09402 002
ESTRADIOL VALERATE
AO STERIS 10MG/ML N83546 001
@ 10MG/ML N83546 001

ESTRONE

INJECTABLE; INJECTION
ESTROGENIC SUBSTANCE
>DLT> BP WYETH AYERST 2MG/ML N83488 001
>ADD> BP + 2MG/ML N83488 001
>DLT>
THEELIN
>DLT> BP + PARKE DAVIS 2MG/ML N03977 002
>ADD> @ 2MG/ML N03977 002

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION
ETHAMOLIN
>DLT> + REED AND CARNRICK 50MG/ML N19357 001 DEC 22, 1988
>DLT>
>ADD> + SPKU 50MG/ML N19357 001 DEC 22, 1988
>ADD>

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
OVCON-35
+ BRISTOL MYERS SQUIBB 0.035MG;0.4MG N18127 001
+ MEAD JOHNSON 0.035MG;0.4MG N18127 001
OVCON-50
@ BRISTOL MYERS SQUIBB 0.05MG;1MG N18128 001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
OVCON-50
+ MEAD JOHNSON — 0.05MG;1MG — N18128 001

TABLET; ORAL-28
OVCON-35
BRISTOL MYERS SQUIBB — 0.035MG;0.4MG — N17716 001
MEAD JOHNSON — 0.035MG;0.4MG — N17716 001
OVCON-50
BRISTOL MYERS SQUIBB — 0.05MG;1MG — N17576 001
MEAD JOHNSON — 0.05MG;1MG — N17576 001

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL
PARSIDOL
PARKE DAVIS — 10MG — N09078 003
50MG — N09078 006
100MG — N09078 008
+ 10MG — N09078 003
@ 50MG — N09078 006
@ 100MG — N09078 008

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE
AP ABBOTT — **20MG/ML** — **N74320 001** AUG 30, 1995
AP — **20MG/ML** — **N74351 001** AUG 30, 1995
AP BEN VENUE — **20MG/ML** — **N74290 001** JUL 17, 1995
AP GENSIA — **20MG/ML** — **N74510 001** JUN 29, 1995
TOPOSAR
AP PHARMACIA — **20MG/ML** — **N74166 001** FEB 27, 1995

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL
+ LABS FOURNIER — 100MG — N19304 001 DEC 31, 1993

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL
@ LABS FOURNIER — 100MG — N19304 001 DEC 31, 1993

FLUDROCORTISONE ACETATE

TABLET; ORAL
FLORINEF
+ APOTHECON — 0.1MG — N10060 001
+ SQUIBB — 0.1MG — N10060 001

FLUNISOLIDE

SPRAY, METERED; NASAL
NASALIDE
BX + SYNTEX — 0.025MG/INH — N18148 001
NASAREL
BX + SYNTEX — 0.025MG/INH — N20409 001 MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA — **0.01%** — **N12787 004**
AT + — **0.025%** — **N12787 002**
AT + — **0.025%** — **N12787 005**
+ — 0.2% — N16161 002
SYNALAR
AT + SYNTEX — **0.01%** — **N12787 004**
AT + — **0.025%** — **N12787 002**
SYNALAR-HP
+ SYNTEX — 0.2% — N16161 002
SYNEMOL
AT + SYNTEX — **0.025%** — **N12787 005**

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA — **0.025%** — **N13960 001**
SYNALAR
AT + SYNTEX — **0.025%** — **N13960 001**

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA — **0.01%** — **N15296 001**

FLUOCINOLONE ACETONIDE

SOLUTION; TOPICAL

	FLUOCINOLONE ACETONIDE		**N88048 001**
AT	PHARMADERM	0.01%	DEC 16, 1982
	@	0.01%	N88048 001 DEC 16, 1982
	SYNALAR		**N15296 001**
AT	+ SYNTEX	0.01%	

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE		**N16908 002**
AB	+ HAMILTON PHARMA CA	0.05%	
	FLUOCINONIDE EMOLLIENT BASE		**N16908 003**
AB	HAMILTON PHARMA CA	0.05%	
	FLUOCINONIDE EMULSIFIED BASE		**N74204 001**
AB	NMC	0.05%	JUN 13, 1995
	LIDEX		**N16908 002**
AB	+ SYNTEX	0.05%	
	LIDEX-E		**N16908 003**
AB	SYNTEX	0.05%	

GEL; TOPICAL

	FLUOCINONIDE		**N17373 001**
AB	+ HAMILTON PHARMA CA	0.05%	
	LIDEX		**N17373 001**
AB	+ SYNTEX	0.05%	

OINTMENT; TOPICAL

	FLUOCINONIDE		**N16909 002**
AB	+ HAMILTON PHARMA CA	0.05%	
	LIDEX		**N16909 002**
AB	+ SYNTEX	0.05%	

SOLUTION; TOPICAL

	FLUOCINONIDE		**N72934 001**
AT	FOUGERA	0.05%	FEB 27, 1995
			N18849 001
AT	+ HAMILTON PHARMA CA	0.05%	APR 06, 1984
	LIDEX		**N18849 001**
AT	+ SYNTEX	0.05%	APR 06, 1984

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	PERMITIL		**N16008 001**
AA	SCHERING	5MG/ML	N16008 001
AA	+	5MG/ML	

FLURBIPROFEN

TABLET; ORAL

	FLURBIPROFEN		**N74448 001**
AB	GENEVA PHARMS	50MG	JUL 28, 1995
			N74448 002
AB		100MG	JUL 28, 1995
			N74431 001
AB	LEMMON	100MG	MAY 31, 1995
			N74405 002
AB	NOVOPHARM	50MG	MAY 24, 1995
			N74405 001
AB		100MG	MAY 24, 1995
			N74411 001
AB	ZENITH LABS	50MG	MAY 31, 1995
			N74411 002
AB		100MG	MAY 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

	FLURBIPROFEN SODIUM		**N74447 001**
AT	BAUSCH AND LOMB	0.03%	JAN 04, 1995
	OCUFEN		**N19404 001**
AT	+ ALLERGAN	0.03%	DEC 31, 1986

FOSINOPRIL SODIUM

TABLET; ORAL

	MONOPRIL		**N19915 003**
	+ BRISTOL MYERS SQUIBB	20MG	MAY 16, 1991
			N19915 003
		20MG	MAY 16, 1991
			N19915 004
	+	40MG	MAR 28, 1995

GEMFIBROZIL

CAPSULE; ORAL

		GEMFIBROZIL		
AB	+	MYLAN	300MG	N73466 001 JAN 25, 1993
	@		300MG	N73466 001 JAN 25, 1993
AB		PUREPAC PHARM	300MG	N72929 001 JAN 29, 1993
	@		300MG	N72929 001 JAN 29, 1993
		LOPID		
AB	+	PARKE DAVIS	300MG	N18422 002
	@		300MG	N18422 002

TABLET; ORAL

		GEMFIBROZIL		
AB		CHELSEA LABS	600MG	N74442 001 APR 28, 1995
> ADD > AB		INVAMED	600MG	N74615 001 SEP 29, 1995
> ADD > AB		MYLAN	600MG	N74452 001 FEB 16, 1995

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

		GENTAMICIN SULFATE		
AT		ADV REMEDIES	EQ 0.3% BASE	N64093 001 AUG 31, 1995

OINTMENT; TOPICAL

		GENTAMICIN SULFATE		
AT		PHARMADERM	EQ 0.1% BASE	N62534 001 OCT 10, 1984
	@		EQ 0.1% BASE	N62534 001 OCT 10, 1984

SOLUTION/DROPS; OPHTHALMIC

		GENTAMICIN SULFATE		
AT		ALCON	EQ 0.3% BASE	N62196 001

GLIPIZIDE

TABLET; ORAL

		GLIPIZIDE		
AB		ALPHAPHARM	5MG	N74438 001 JUN 20, 1995
AB			10MG	N74438 002 JUN 20, 1995
AB		BAKER NORTON	5MG	N74497 001 AUG 31, 1995
AB			10MG	N74497 002 AUG 31, 1995
AB		GENEVA PHARMS	5MG	N74305 001 APR 07, 1995
AB			10MG	N74305 002 APR 07, 1995
AB		INVAMED	5MG	N74542 001 JUN 20, 1995
AB			10MG	N74542 002 JUN 20, 1995
AB		WATSON LABS	5MG	N74223 001 FEB 27, 1995
AB			10MG	N74223 002 FEB 27, 1995

GLYBURIDE

TABLET; ORAL

		GLUBATE		
	@	HOECHST ROUSSEL	1.5MG	N20055 001 APR 17, 1992
	@		3MG	N20055 002 APR 17, 1992
		GLYBURIDE		
AB		NOVOPHARM	1.25MG	N74388 001 AUG 29, 1995
AB			2.5MG	N74388 002 AUG 29, 1995
AB			5MG	N74388 003 AUG 29, 1995
		GLYBURIDE (MICRONIZED)		
AB		HOECHST ROUSSEL	1.5MG	N20055 001 APR 17, 1992
AB			3MG	N20055 002 APR 17, 1992
		GLYNASE		
AB		UPJOHN	1.5MG	N20051 001 MAR 04, 1992

GLYBURIDE

TABLET; ORAL

	GLYNASE			
AB	UPJOHN	**3MG**	**N20051 002**	
			MAR 04, 1992	
	MICRONASE			
AB	UPJOHN	**1.25MG**	**N17498 001**	
			MAY 01, 1984	
AB		**2.5MG**	**N17498 002**	
			MAY 01, 1984	
AB	+	**5MG**	**N17498 003**	
			MAY 01, 1984	

GLYCINE

SOLUTION; IRRIGATION

	GLYCINE 1.5% IN PLASTIC CONTAINER			
AT	BAXTER	**1.5GM/100ML**	**N18522 001**	
			FEB 19, 1982	
	@	1.5GM/100ML	N18522 001	
			FEB 19, 1982	

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

	KYTRIL			
	+ SMITHKLINE BEECHAM	EQ 1MG BASE	N20305 001	
			MAR 16, 1995	

GUANABENZ ACETATE

TABLET; ORAL

	GUANABENZ ACETATE			
AB	ZENITH LABS	**EQ 4MG BASE**	**N74149 001**	
			APR 07, 1995	
AB		**EQ 8MG BASE**	**N74149 002**	
			APR 07, 1995	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	TENEX			
	ROBINS AH	1MG	N19032 001	
			OCT 27, 1986	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	TENEX			
	+ ROBINS AH	2MG	N19032 002	
			NOV 07, 1988	
	@	3MG	N19032 003	
			NOV 07, 1988	
		EQ 1MG BASE	N19032 001	
			OCT 27, 1986	
	+	EQ 2MG BASE	N19032 002	
			NOV 07, 1988	
	@	EQ 3MG BASE	N19032 003	
			NOV 07, 1988	

HALCINONIDE

CREAM; TOPICAL

	HALOG			
AT	+ WESTWOOD SQUIBB	**0.1%**	**N17556 001**	
	+	0.1%	N17556 001	
	HALOG-E			
AT	WESTWOOD SQUIBB	**0.1%**	**N18234 001**	
		0.1%	N18234 001	

HEPARIN CALCIUM

INJECTABLE; INJECTION

	CALCIPARINE			
	+ CHOAY	25,000 UNITS/ML	N18237 001	
	@ SANOFI WINTHROP	25,000 UNITS/ML	N18237 001	

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN LOCK FLUSH			
AP	SANOFI WINTHROP	**10 UNITS/ML**	**N40082 001**	
			FEB 28, 1995	
AP		**100 UNITS/ML**	**N40082 002**	
			FEB 28, 1995	
	HEPARIN SODIUM			
AP	+ ABBOTT	**2,500 UNITS/ML**	**N05264 014**	
			APR 07, 1986	
	+	2,000 UNITS/ML	N05264 013	
			APR 07, 1986	

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP		ELKINS SINN	10,000 UNITS/ML	N17037 013 APR 07, 1986	
AP			5,000 UNITS/0.5ML	N17037 013 APR 07, 1986	
AP		PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	
AP		WYETH AYERST	2,500 UNITS/ML	N17007 007	
AP	+		2,500 UNITS/ML	N17007 007	

HEPARIN SODIUM 1000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		MCGAW	200 UNITS/100ML	N19130 001 DEC 31, 1984	
	@		200 UNITS/100ML	N19130 001 DEC 31, 1984	

HEPARIN SODIUM 1000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		MCGAW	200 UNITS/100ML	N19042 001 MAR 29, 1985	
	@		200 UNITS/100ML	N19042 001 MAR 29, 1985	

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

> DLT >	AP	ABBOTT	5,000 UNITS/100ML	N18916 006 JAN 31, 1984		
> DLT >						
> ADD >			5,000 UNITS/100ML	N18916 006 JAN 31, 1984		
> ADD >						

HEPARIN SODIUM 12500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

> DLT >						
> DLT >	AP	MCGAW	5,000 UNITS/100ML	N19802 001 JUL 20, 1992		
> DLT >						
> ADD >	@		5,000 UNITS/100ML	N19802 001 JUL 20, 1992		
> ADD >						

HEPARIN SODIUM 2000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		MCGAW	200 UNITS/100ML	N19130 003 DEC 31, 1984	
	@		200 UNITS/100ML	N19130 003 DEC 31, 1984	

HEPARIN SODIUM 2000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		MCGAW	200 UNITS/100ML	N19042 002 MAR 29, 1985	
	@		200 UNITS/100ML	N19042 002 MAR 29, 1985	

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

> DLT >	AP	ABBOTT	5,000 UNITS/100ML	N18916 007 JAN 31, 1984		
> DLT						
> DLT >	AP		10,000 UNITS/100ML	N18916 008 JAN 31, 1984		
> DLT >						
> ADD >			5,000 UNITS/100ML	N18916 007 JAN 31, 1984		
> ADD >						
> ADD >			10,000 UNITS/100ML	N18916 008 JAN 31, 1984		
> ADD >						

HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

> DLT >						
> DLT >	AP	MCGAW	5,000 UNITS/100ML	N19802 005 JUL 20, 1992		
> DLT >						
> DLT >	AP		10,000 UNITS/100ML	N19802 002 JUL 20, 1992		
> DLT >						
> ADD >	@		5,000 UNITS/100ML	N19802 005 JUL 20, 1992		
> ADD >						
> ADD >	@		10,000 UNITS/100ML	N19802 002 JUL 20, 1992		
> ADD >						

HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> DLT >		MCGAW	5,000 UNITS/100ML	N19802 003 JUL 20, 1992		
> DLT >						
> ADD >	@		5,000 UNITS/100ML	N19802 003 JUL 20, 1992		
> ADD >						

HEPARIN SODIUM 5000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		MCGAW	1,000 UNITS/100ML	N19130 002 DEC 31, 1984	
	@		1,000 UNITS/100ML	N19130 002 DEC 31, 1984	

HEPARIN SODIUM PRESERVATIVE FREE

AP	+	ABBOTT	2,500 UNITS/ML	N05264 014 APR 07, 1986	
	+		2,000 UNITS/ML	N05264 013 APR 07, 1986	
AP		FUJISAWA	1,000 UNITS/ML	N17029 010 APR 28, 1986	
AP	+		1,000 UNITS/ML	N17029 010 APR 28, 1986	
AP		PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	
AP		STERLING WINTHROP	10,000 UNITS/ML	N89522 001 MAY 04, 1987	
AP	+		10,000 UNITS/ML	N89522 001 MAY 04, 1987	

HEPARIN SODIUM

INJECTABLE; INJECTION

	LIQUAEMIN LOCK FLUSH			
AP	ORGANON	**100 UNITS/ML**		**N00552 007**
@		100 UNITS/ML		N00552 007
	LIQUAEMIN SODIUM			
AP	ORGANON	**1,000 UNITS/ML**		**N00552 004**
AP		**5,000 UNITS/ML**		**N00552 003**
AP		**10,000 UNITS/ML**		**N00552 005**
@		1,000 UNITS/ML		N00552 004
@		5,000 UNITS/ML		N00552 003
@		10,000 UNITS/ML		N00552 005

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	DRALZINE			
AA	LEMMON	**25MG**		**N84301 001**
@		25MG		N84301 001
	HYDRALAZINE HCL			
AA	HALSEY	**50MG**		**N89222 001**
				JAN 22, 1986
@		50MG		N89222 001
				JAN 22, 1986

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	APRESOLINE-ESIDRIX			
+	CIBA	25MG;15MG		N12026 002
@		25MG;15MG		N12026 002

HYDROCHLOROTHIAZIDE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE			
AB	ASCOT	**50MG**		**N87540 001**
				FEB 03, 1982
@		50MG		N87540 001
				FEB 03, 1982
AB	INWOOD LABS	**25MG**		**N85067 001**
@		25MG		N85067 001

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

	HYZAAR			
+	MERCK	12.5MG;50MG		N20387 001
				APR 28, 1995

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

	LOPRESSOR HCT			
	CIBA	25MG;50MG		N18303 001
				DEC 31, 1984
		25MG;100MG		N18303 002
				DEC 31, 1984
+		50MG;100MG		N18303 003
				DEC 31, 1984
	LOPRESSOR HCT 100/25			
	CIBA	25MG;100MG		N18303 002
				DEC 31, 1984
	LOPRESSOR HCT 100/50			
+	CIBA	50MG;100MG		N18303 003
				DEC 31, 1984
	LOPRESSOR HCT 50/25			
	CIBA	25MG;50MG		N18303 001
				DEC 31, 1984

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE			
AB	WARNER CHILCOTT	**25MG;80MG**		**N71772 001**
				JAN 26, 1988
@		25MG;80MG		N71772 001
				JAN 26, 1988

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	ZENITH LABS	**25MG;50MG**		**N74259 001**
				MAR 30, 1995

HYDROCORTISONE

CREAM; TOPICAL

> DLT >		**FLEXICORT**		
> DLT >	**AT**	WESTWOOD SQUIBB	**0.5%**	**N87136 003 APR 08, 1982**
> DLT >	**AT**		**1%**	**N87136 002 APR 08, 1982**
> DLT >	**AT**		**2.5%**	**N87136 001 APR 08, 1982**
> ADD >		@	0.5%	N87136 003 APR 08, 1982
> ADD >		@	1%	N87136 002 APR 08, 1982
> ADD >		@	2.5%	N87136 001 APR 08, 1982
		HYDROCORTISONE		
	AT	CLAY PARK	**0.5%**	**N84970 002**
	AT		**1%**	**N85026 001**
		@	0.5%	N84970 002
		@	1%	N85026 001

ENEMA; RECTAL

		CORTENEMA		
		+	100MG/60ML	N16199 001
	BR	+ SOLVAY	100MG/60ML	N16199 001
		HYDROCORTISONE		
	BR	COPLEY PHARM	100MG/60ML	N74171 001 MAY 27, 1994
		@	100MG/60ML	N74171 001 MAY 27, 1994

LOTION; TOPICAL

		HYDROCORTISONE		
	AT	CLAY PARK	**0.5%**	**N85662 001**
		@	0.5%	N85662 001

OINTMENT; TOPICAL

		HYDROCORTISONE		
		CLAY PARK	0.5%	N84969 003
		@	0.5%	N84969 003

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		CORTISPORIN		
AT	+	BURROUGHS WELLCOME	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N50479 001**

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		CORTISPORIN		
AT	+	BURROUGHS WELLCOME	**10.1MG/ML;EQ 3.5MG BASE/ML; 12,000 UNITS/ML**	**N50479 001**

HYDROCORTISONE; UREA

CREAM; TOPICAL

		ALPHADERM		
AT		VIVAN	**1%;10%**	**N86008 001**
		@	1%;10%	N86008 001
		CALMURID HC		
AT	+	PHARMACIA	**1%;10%**	**N83947 001**
		@	1%;10%	N83947 001

HYDROCORTISONE ACETATE

AEROSOL; RECTAL

		CORTIFOAM		
	+	REED AND CARNRICK	10%	N17351 001 FEB 10, 1982
	+	SPKU	10%	N17351 001 FEB 10, 1982

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL; TOPICAL

		PROCTOFOAM HC		
BX		REED AND CARNRICK	1%;1%	N86195 001
BX		SPKU	1%;1%	N86195 001

HYDROCORTISONE BUTYRATE

OINTMENT; TOPICAL

> ADD >		LOCOID		
> ADD >		@ YAMANOUCHI	0.1%	N18652 001 OCT 29, 1982
> DLT >				
> DLT >				
> ADD >	+		0.1%	N18652 001 OCT 29, 1982
> ADD >				

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

		DILAUDID-HP		
AP	+	KNOLL PHARM	**10MG/ML**	**N19034 001** JAN 11, 1984
		HYDROMORPHONE HCL		
AP		STERIS	**10MG/ML**	**N74317 001** AUG 23, 1995

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

		HYDROXYPROGESTERONE CAPROATE		
>DLT>	+	AKORN	125MG/ML	N18004 001
>ADD>	@		125MG/ML	N18004 001

HYDROXYUREA

CAPSULE; ORAL

		HYDREA		
AB	+	SQUIBB	**500MG**	**N16295 001**
		HYDROXYUREA		
AB		ROXANE	**500MG**	**N74476 001** AUG 18, 1995

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		HYDROXYZINE HCL		
AP		PHARMAFAIR	**50MG/ML**	**N88881 001** FEB 14, 1986
	@		50MG/ML	N88881 001 FEB 14, 1986
AP		STERIS	**25MG/ML**	**N87274 001**
AP			**50MG/ML**	**N87274 002**
	@		25MG/ML	N87274 001
	@		50MG/ML	N87274 002

SYRUP; ORAL

		HYDROXYZINE HCL		
AA		BARRE	**10MG/5ML**	**N88785 001** FEB 03, 1988
	@		10MG/5ML	N88785 001 FEB 03, 1988

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

		HYDROXYZINE HCL		
AB		HALSEY	**50MG**	**N89396 001** MAY 02, 1988
	@		50MG	N89396 001 MAY 02, 1988
>ADD> **AB**		SIDMAK LABS NJ	**100MG**	**N81054 001** SEP 25, 1995
>ADD>				

IBUPROFEN

SUSPENSION; ORAL

		CHILDREN'S MOTRIN		
BX	+	MCNEIL CONS PRODS	100MG/5ML	N19842 001 SEP 19, 1989
		PEDIA PROFEN		
BX	+	MCNEIL CONS PRODS	100MG/5ML	**N19842 001** SEP 19, 1989

SUSPENSION/DROPS; ORAL

		MOTRIN		
	+	MCNEIL CONS PRODS	40MG/ML	N20476 001 MAY 25, 1995

INDAPAMIDE

TABLET; ORAL

		INDAPAMIDE		
AB		ZENITH LABS	**2.5MG**	**N74299 001** JUL 27, 1995
		LOZOL		
AB	+	RHONE POULENC RORER	**2.5MG**	**N18538 001** JUL 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		DECABID		
		LILLY	EQ 50MG BASE	N19693 001 DEC 29, 1989
			EQ 75MG BASE	N19693 002 DEC 29, 1989
	+		EQ 100MG BASE	N19693 003 DEC 29, 1989

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID			
@ LILLY	EQ 50MG BASE	N19693 001	DEC 29, 1989
@	EQ 75MG BASE	N19693 002	DEC 29, 1989
@	EQ 100MG BASE	N19693 003	DEC 29, 1989

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE			
+ CYPROS	100MG/ML	N02282 001	
+ ISO TEX	100MG/ML	N02282 001	

IOCETAMIC ACID

TABLET; ORAL

CHOLEBRINE			
+ MALLINCKRODT	750MG	N17129 001	
@	750MG	N17129 001	

IOPAMIDOL

INJECTABLE; INTRAVASCULAR

> DLT > ISOVUE-200			
> ADD > @ BRACCO	41%	N20327 001	OCT 12, 1994
> ADD >			
> DLT > BRACCO DXS	41%	N20327 001	OCT 12, 1994
> DLT >			

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST			
+ BERLEX	EQ 150MG IODINE/ML	N20220 004	MAY 10, 1995
+	EQ 240MG IODINE/ML	N20220 003	MAY 10, 1995
+	EQ 300MG IODINE/ML	N20220 002	MAY 10, 1995

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST			
+ BERLEX	EQ 370MG IODINE/ML	N20220 001	MAY 10, 1995

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY			
+ MALLINCKRODT	80%	N13319 001	
@	80%	N13319 001	

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION

GLOFIL-125			
> ADD > CYPROS	250-300 uCi/ML	N17279 001	
> DLT > ISO TEX	250-300 uCi/ML	N17279 001	

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST			
@ BERLEX	EQ 190MG IODINE/ML	N19580 001	DEC 07, 1989
@	EQ 240MG IODINE/ML	N19580 002	DEC 07, 1989
	EQ 190MG IODINE/ML	N19580 001	DEC 07, 1989
	EQ 240MG IODINE/ML	N19580 002	DEC 07, 1989

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HCL S/F			
AN + DEY	1%	N89252 001	SEP 15, 1986
@	1%	N89252 001	SEP 15, 1986

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE

AN	MARSAM	99.9%	N74393 001 MAY 12, 1995
AN	RHONE POULENC	99.9%	N74502 001 JUN 27, 1995

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

BC	REED AND CARNRICK	40MG	N19790 001 SEP 02, 1988
BC	SPKU	40MG	N19790 001 SEP 02, 1988

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
IMDUR

	@ SCHERING	30MG	N20225 001 AUG 12, 1993
	+	60MG	N20225 002 AUG 12, 1993
	+	120MG	N20225 003 MAR 30, 1995
	@ SCHERING PLOUGH	30MG	N20225 001 AUG 12, 1993
	+	60MG	N20225 002 AUG 12, 1993

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN

AP	ELKINS SINN	EQ 75MG BASE/2ML	N62324 001
AP		EQ 500MG BASE/2ML	N62324 002
AP		EQ 1GM BASE/3ML	N62324 003
	@	EQ 75MG BASE/2ML	N62324 001
	@	EQ 500MG BASE/2ML	N62324 002
	@	EQ 1GM BASE/3ML	N62324 003

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

	+ WYETH AYERST	100MG	N19816 003 FEB 08, 1995
	+	150MG	N19816 002 FEB 08, 1995

LACTULOSE

SOLUTION; ORAL
LACTULOSE

AA	HI TECH PHARMA	10GM/15ML	N74076 001 JUL 03, 1995

SOLUTION; ORAL, RECTAL
LACTULOSE

AA	HI TECH PHARMA	10GM/15ML	N74077 001 JUL 03, 1995

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL
PREVACID

	TAP HOLDINGS	15MG	N20406 001 MAY 10, 1995
	+	30MG	N20406 002 MAY 10, 1995

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

	+ CETUS BEN VENUE	EQ 200MG BASE/VIAL	N40056 001 MAY 23, 1995

WELLCOVORIN

AP	BURROUGHS WELLCOME	EQ 50MG BASE/VIAL	N89465 001 JAN 23, 1989
	+	EQ 25MG BASE/VIAL	N89833 001 JAN 23, 1989
	@	EQ 25MG BASE/VIAL	N89833 001 JAN 23, 1989
	@	EQ 50MG BASE/VIAL	N89465 001 JAN 23, 1989

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON
TAP HOLDINGS 5MG/ML N20263 001 APR 16, 1993
\+ 1MG/0.2ML N19010 001 APR 09, 1985
\+ TAP PHARMS 5MG/ML N19010 001 APR 09, 1985

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
AP AKORN 1% N85037 001
AP 2% N85037 002
@ 1% N85037 001
@ 2% N85037 002
> DLT > AP FUJISAWA 2% N80420 004
> ADD > @ 2% N80420 004
AP SANOFI WINTHROP 1% N40013 001 JUN 23, 1995
AP 2% N40078 001 JUN 23, 1995

SOLUTION; ORAL
LIDOCAINE HCL
AT HI TECH PHARMA 2% N40014 001 JUL 10, 1995

LINDANE

LOTION; TOPICAL
SCABENE
AT STIEFEL 1% N86769 001
@ 1% N86769 001

SHAMPOO; TOPICAL
SCABENE
AT STIEFEL 1% N87940 001 APR 08, 1983
@ 1% N87940 001 APR 08, 1983

LISINOPRIL

TABLET; ORAL
PRINIVIL
AB MERCK 2.5MG N19558 006 JAN 28, 1994
2.5MG N19558 006 JAN 28, 1994
ZESTRIL
AB ZENECA 2.5MG N19777 005 APR 29, 1993
@ 2.5MG N19777 005 APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL
LITHOTABS
AB SOLVAY 300MG N16980 001
AB \+ 300MG N16980 001

TABLET, EXTENDED RELEASE; ORAL
LITHOBID
@ SOLVAY 300MG N18027 001
300MG N18027 001

LOSARTAN POTASSIUM

TABLET; ORAL
COZAAR
MERCK 25MG N20386 001 APR 14, 1995
\+ 50MG N20386 002 APR 14, 1995

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION
PHYSIOLYTE IN PLASTIC CONTAINER
AT MCGAW 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19024 001 JUN 08, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

	MCGAW	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19024 001 JUN 08, 1984	

PHYSIOSOL IN PLASTIC CONTAINER

AT	ABBOTT	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N17637 002 JUL 08, 1982	
		30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N17637 002 JUL 08, 1982	

SYNOVALYTE IN PLASTIC CONTAINER

AT	BAXTER	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N19326 001 JAN 25, 1985	
	@	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N19326 001 JAN 25, 1985	

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	ABBOTT	1GM/100ML	N20488 001 JUL 11, 1995	
	+	2GM/100ML	N20488 002 JUL 11, 1995	

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

AP	ABBOTT	10GM/100ML	N16269 002	
	@	10GM/100ML	N16269 002	

MANNITOL 15%

AP	ABBOTT	15GM/100ML	N16269 003	
	@	15GM/100ML	N16269 003	

MANNITOL 20%

AP	ABBOTT	20GM/100ML	N16269 004	
	@	20GM/100ML	N16269 004	

MANNITOL 25%

AP	ABBOTT	12.5GM/50ML	N16269 005	

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

AP	ABBOTT	12.5GM/50ML	N16269 006 AUG 25, 1994	
	@	12.5GM/50ML	N16269 005	

MANNITOL 5%

AP	ABBOTT	5GM/100ML	N16269 001	
	@	5GM/100ML	N16269 001	

MASOPROCOL

CREAM; TOPICAL

ACTINEX

	+ BLOCK DRUG	10%	N19940 001 SEP 04, 1992	
	+ SPKU	10%	N19940 001 SEP 04, 1992	

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

AB	COPLEY PHARM	100MG	N73580 001 JAN 04, 1995	

VERMOX

AB	+ JANSSEN	100MG	N17481 001	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

> DLT >	+ UPJOHN	100MG/ML	N12541 002	
> ADD >	@	100MG/ML	N12541 002	

MEGESTROL ACETATE

TABLET; ORAL

MEGACE

AB	BRISTOL MYERS SQUIBB	20MG	N16979 001	
AB	+	40MG	N16979 002	
AB	MEAD JOHNSON	20MG	N16979 001	
AB	+	40MG	N16979 002	

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

> ADD >	**AB**	ROXANE	**20MG**	**N74458 001**	
				SEP 29, 1995	
> ADD					
> ADD >	**AB**		**40MG**	**N74458 002**	
				SEP 29, 1995	
> ADD >					

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE

AN	BARRE	**0.4%**	**N71855 001**		
			JUL 14, 1988		
AN		**0.6%**	**N71726 001**	> ADD >	
			JUL 14, 1988	> ADD >	
AN	PACO	**0.4%**	**N71855 001**	> ADD >	
			JUL 14, 1988	> DLT >	
AN		**0.6%**	**N71726 001**	> DLT >	
			JUL 14, 1988	> DLT >	

SYRUP; ORAL
ALUPENT

AA	BOEHRINGER INGELHEIM	**10MG/5ML**	**N17571 001**
AA	+	**10MG/5ML**	**N17571 001**

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

	BRISTOL MYERS SQUIBB	500MG	N20357 001
			DEC 29, 1994
	+	850MG	N20357 002
			DEC 29, 1994
	LIPHA	500MG	N20357 001
			DEC 29, 1994
	+	850MG	N20357 002
			DEC 29, 1994

METHADONE HYDROCHLORIDE

POWDER; FOR RX COMPOUNDING
METHADONE HCL

MALLINCKRODT	50GM/BOT	N06383 002
	100GM/BOT	N06383 003

METHADONE HYDROCHLORIDE

POWDER; FOR RX COMPOUNDING
METHADONE HCL

MALLINCKRODT	500GM/BOT	N06383 004

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	ROXANE	**40MG**	**N74081 001**
			APR 28, 1995

METHICILLIN SODIUM

INJECTABLE; INJECTION
STAPHCILLIN

@	APOTHECON	EQ 900MG BASE/VIAL	N50117 001
@		EQ 3.6GM BASE/VIAL	N50117 002
@		EQ 5.4GM BASE/VIAL	N50117 003
@	BRISTOL	EQ 900MG BASE/VIAL	N50117 001
@		EQ 3.6GM BASE/VIAL	N50117 002
@		EQ 5.4GM BASE/VIAL	N50117 003

METHOTRIMEPRAZINE

INJECTABLE; INJECTION
LEVOPROME

+	IMMUNEX	20MG/ML	N15865 001
+	LEDERLE	20MG/ML	N15865 001

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP	DUPONT MERCK	**50MG/ML**	**N70691 001**
			JUN 19, 1987
AP		**50MG/ML**	**N70849 001**
			JUN 19, 1987
AP	FAULDING	**50MG/ML**	N70691 001
			JUN 19, 1987
AP		**50MG/ML**	N70849 001
			JUN 19, 1987

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE

BP	AKORN	40MG/ML	N86903 001	OCT 20, 1982
BP		80MG/ML	N86903 002	OCT 20, 1982
@		40MG/ML	N86903 001	OCT 20, 1982
@		80MG/ML	N86903 002	OCT 20, 1982

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	DUPONT MERCK	EQ 10MG BASE/2ML	N70847 001	NOV 07, 1988
AP		EQ 10MG BASE/2ML	N71291 001	MAR 03, 1989
AP	FAULDING	EQ 10MG BASE/2ML	N70847 001	NOV 07, 1988
AP		EQ 10MG BASE/2ML	N71291 001	MAR 03, 1989

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL
LOPRESSOR

	GEIGY	EQ 100MG TARTRATE	N19786 001	DEC 27, 1989
		EQ 200MG TARTRATE	N19786 002	DEC 27, 1989
		EQ 300MG TARTRATE	N19786 003	DEC 27, 1989
		EQ 400MG TARTRATE	N19786 004	DEC 27, 1989
+		EQ 100MG TARTRATE	N19786 001	DEC 27, 1989
@		EQ 200MG TARTRATE	N19786 002	DEC 27, 1989
@		EQ 300MG TARTRATE	N19786 003	DEC 27, 1989
@		EQ 400MG TARTRATE	N19786 004	DEC 27, 1989

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB	LEMMON	50MG	N74141 001	JAN 31, 1995
AB		100MG	N74141 002	JAN 31, 1995
AB	PAR PHARM	50MG	N74453 001	APR 27, 1995
AB		100MG	N74453 002	APR 27, 1995

METRONIDAZOLE

CAPSULE; ORAL
FLAGYL

+	SEARLE	375MG	N20334 001	MAY 03, 1995

CREAM; TOPICAL
METROCREAM

+	GALDERMA	0.75%	N20531 001	SEP 20, 1995

METYRAPONE

TABLET; ORAL
METOPIRONE

+	CIBA	250MG	N12911 001	
@		250MG	N12911 001	

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	NOVOPHARM	150MG	N74377 001	MAY 16, 1995
AB		200MG	N74377 002	MAY 16, 1995
AB		250MG	N74377 003	MAY 16, 1995

MEXITIL

AB	BOEHRINGER INGELHEIM	150MG	N18873 002	DEC 30, 1985

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXITIL

AB	BOEHRINGER INGELHEIM	200MG	N18873 003	DEC 30, 1985
AB +		250MG	N18873 004	DEC 30, 1985

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ABLE	200MG	N73508 001	NOV 19, 1993
AB	NMC	200MG	N73508 001	NOV 19, 1993

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	CETUS BEN VENUE	5MG/VIAL	N64117 001	APR 19, 1995
		20MG/VIAL	N64117 002	APR 19, 1995

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
UNIVASC

	SPKU	7.5MG	N20312 001	APR 19, 1995
+		15MG	N20312 002	APR 19, 1995

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN

>ADD> >ADD>	BC +	PURDUE FREDERICK	15MG	N19516 003	SEP 12, 1989

ORAMORPH SR

>ADD> >ADD>	BC	ROXANE	15MG	N19977 004	NOV 23, 1994

>ADD> MUPIROCIN CALCIUM

>ADD> OINTMENT; NASAL
>ADD> BACTROBAN
>ADD> + SMITHKLINE BEECHAM EQ 2% ACID N50703 001
>ADD> SEP 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL
CELLCEPT

+	SYNTEX	250MG	N50722 001	MAY 03, 1995

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001	AUG 02, 1984
AP		EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N61984 002	AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62527 002	AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62732 001	DEC 23, 1986
AP		EQ 2GM BASE/VIAL	N61984 003	AUG 02, 1984
AP		EQ 2GM BASE/VIAL	N62527 003	AUG 02, 1984
AP		EQ 2GM BASE/VIAL	N62732 002	DEC 23, 1986
AP		EQ 4GM BASE/VIAL	N61984 005	AUG 02, 1984
AP		EQ 10GM BASE/VIAL	N62527 004	AUG 02, 1984

NAFCILLIN SODIUM

AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001	AUG 02, 1984
AP		EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N61984 002	AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62527 002	AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62732 001	DEC 23, 1986
AP		EQ 2GM BASE/VIAL	N61984 003	AUG 02, 1984
AP		EQ 2GM BASE/VIAL	N62527 003	AUG 02, 1984

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

AP	APOTHECON	EQ 2GM BASE/VIAL	N62732 002	
			DEC 23, 1986	
AP		EQ 4GM BASE/VIAL	N61984 005	
AP		EQ 10GM BASE/VIAL	N62527 004	
			AUG 02, 1984	

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX

	OHMEDA	EQ 0.1MG BASE/ML	N20459 001	
			APR 17, 1995	
+		EQ 1MG BASE/ML	N20459 002	
			APR 17, 1995	

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP	FUJISAWA	0.02MG/ML	N70648 001	
			NOV 17, 1986	
AP		0.4MG/ML	N70649 001	
			NOV 17, 1986	
@		0.02MG/ML	N70648 001	
			NOV 17, 1986	
@		0.4MG/ML	N70649 001	
			NOV 17, 1986	
> DLT > AP	MARSAM	0.4MG/ML	N71811 001	
> DLT >			JUL 19, 1988	
> ADD > @		0.4MG/ML	N71811 001	
> ADD >			JUL 19, 1988	

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AQ	AKORN	100MG/ML	N87519 001	
			SEP 28, 1983	
@		100MG/ML	N87519 001	
			SEP 28, 1983	

NAPROXEN

TABLET; ORAL
NAPROXEN

AB	CHELSEA LABS	250MG	N74457 001	
			MAY 31, 1995	
AB		375MG	N74457 002	
			MAY 31, 1995	
AB		500MG	N74457 003	
			MAY 31, 1995	
AB	DANBURY PHARMA	250MG	N74163 001	
			FEB 10, 1995	
AB		375MG	N74163 002	
			FEB 10, 1995	
AB		500MG	N74163 003	
			FEB 10, 1995	
AB	MOVA	250MG	N74410 001	
			APR 28, 1995	
AB		375MG	N74410 002	
			APR 28, 1995	
AB		500MG	N74410 003	
			APR 28, 1995	
AB	ZENITH LABS	250MG	N74111 001	
			FEB 28, 1995	
AB		375MG	N74111 002	
			FEB 28, 1995	
AB		500MG	N74111 003	
			FEB 28, 1995	

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	CHELSEA LABS	EQ 250MG BASE	N74455 001	
			MAY 31, 1995	
AB		EQ 500MG BASE	N74455 002	
			MAY 31, 1995	
AB	PUREPAC PHARM	EQ 250MG BASE	N74319 001	
			MAR 20, 1995	
AB		EQ 500MG BASE	N74319 002	
			MAR 20, 1995	
AB	ZENITH LABS	EQ 250MG BASE	N74230 001	
			MAR 14, 1995	
AB		EQ 500MG BASE	N74230 002	
			MAR 14, 1995	

NEOMYCIN SULFATE

TABLET; ORAL

		NEOMYCIN SULFATE		
AA		BIOCRAFT	EQ 350MG BASE	N60304 001
			EQ 350MG BASE	N60304 001
AA		LILLY	EQ 350MG BASE	N60385 001
	@		EQ 350MG BASE	N60385 001

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

		HABITROL		
BC	+	BASEL PHARMS	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991
BC	+	CIBA	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

		NICORETTE		
	+	MERRELL DOW	EQ 2MG BASE	N18612 001 JAN 13, 1984
	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 001 JAN 13, 1984
		NICORETTE DS		
	+	MERRELL DOW	EQ 4MG BASE	N20066 001 JUN 08, 1992
	+	SMITHKLINE BEECHAM	EQ 4MG BASE	N20066 001 JUN 08, 1992

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

		NISOCOR		
	+	BAYER	10MG	N20356 001 FEB 02, 1995
	+		20MG	N20356 002 FEB 02, 1995
	+		30MG	N20356 003 FEB 02, 1995
	+		40MG	N20356 004 FEB 02, 1995
	+	ZENECA	10MG	N20356 001 FEB 02, 1995
	+		20MG	N20356 002 FEB 02, 1995
	+		30MG	N20356 003 FEB 02, 1995
	+		40MG	N20356 004 FEB 02, 1995

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

		NITROFURANTOIN		
AB		GENEVA PHARMS	25MG	N74336 001 JAN 25, 1995
AB			50MG	N74336 002 JAN 25, 1995
AB			100MG	N74336 003 JAN 25, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

		NITRO-DUR		
	+	KEY PHARMS	0.1MG/HR	N20145 001 APR 04, 1995
	+		0.2MG/HR	N20145 002 APR 04, 1995
	+		0.3MG/HR	N20145 003 APR 04, 1995
	+		0.4MG/HR	N20145 004 APR 04, 1995
	+		0.6MG/HR	N20145 005 APR 04, 1995
	+		0.8MG/HR	N20145 006 APR 04, 1995

NITROGLYCERIN

INJECTABLE; INJECTION

	NITROGLYCERIN				
AP	**FUJISAWA**	**5MG/ML**	**N70077 001**		
			DEC 13, 1985		
	@	5MG/ML	N70077 001		
			DEC 13, 1985		
	NITROSTAT				
AP	**PARKE DAVIS**	**5MG/ML**	**N18588 002**		
			DEC 23, 1983		
	+	**0.8MG/ML**	**N18588 001**		
	@	0.8MG/ML	N18588 001		
	@	5MG/ML	N18588 002		
			DEC 23, 1983		
	TRIDIL				
AP	**DUPONT MERCK**	**5MG/ML**	**N18537 001**		
	+	**0.5MG/ML**	**N18537 002**		
			JUN 16, 1983		
AP	FAULDING	**5MG/ML**	**N18537 001**		
	+	0.5MG/ML	N18537 002		
			JUN 16, 1983		

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL				
AB	LEMMON	**EQ 10MG BASE**	**N74132 001**		
			MAR 27, 1995		
AB		**EQ 25MG BASE**	**N74132 002**		
			MAR 27, 1995		
AB		**EQ 50MG BASE**	**N74132 003**		
			MAR 27, 1995		
AB		**EQ 75MG BASE**	**N74132 004**		
			MAR 27, 1995	> ADD >	
				> DLT >	

NYSTATIN

TABLET; ORAL

	MYCOSTATIN				
AA	+ APOTHECON	**500,000 UNITS**	**N60574 001**		
AA	+ SQUIBB	**500,000 UNITS**	**N60574 001**	> ADD >	
				> DLT >	

TABLET; VAGINAL

	NYSTATIN				
AT	LEMMON	**100,000 UNITS**	**N62502 001**		
			DEC 23, 1983		

NYSTATIN

TABLET; VAGINAL

	NYSTATIN				
	@ LEMMON	100,000 UNITS	N62502 001		
			DEC 23, 1983		

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	NYSTATIN AND TRIAMCINOLONE ACETONIDE				
AT	**PHARMAFAIR**	**100,000 UNITS/GM;0.1%**	**N62656 001**		
			JUL 30, 1986		
	@	100,000 UNITS/GM;0.1%	N62656 001		
			JUL 30, 1986		

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

	ZOFRAN IN PLASTIC CONTAINER				
	+ GLAXO	EQ 0.64MG BASE/ML	N20403 001		
			JAN 31, 1995		

OXACILLIN SODIUM

CAPSULE; ORAL

	OXACILLIN SODIUM				
AB	APOTHECON	**EQ 250MG BASE**	**N61450 002**		
AB	+	**EQ 500MG BASE**	**N61450 001**		
	PROSTAPHLIN				
AB	APOTHECON	**EQ 250MG BASE**	**N61450 002**		
AB	+	**EQ 500MG BASE**	**N61450 001**		
	@	EQ 500MG BASE	N50118 002		
	@ BRISTOL	EQ 500MG BASE	N50118 002		

POWDER FOR RECONSTITUTION; ORAL

	OXACILLIN SODIUM				
AA	APOTHECON	**EQ 250MG BASE/5ML**	**N61457 001**		
	PROSTAPHLIN				
AA	APOTHECON	**EQ 250MG BASE/5ML**	**N61457 001**		
	@	EQ 250MG BASE/5ML	N50194 001		
	@ BRISTOL	EQ 250MG BASE/5ML	N50194 001		

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

	DARICON			
+	PFIZER	10MG		N11612 001
@		10MG		N11612 001

PENBUTOLOL SULFATE

TABLET; ORAL

	LEVATOL			
@	REED AND CARNRICK	10MG		N18976 001
				DEC 30, 1987
+		20MG		N18976 004
				JAN 05, 1989
@	SPKU	10MG		N18976 001
				DEC 30, 1987
+		20MG		N18976 004
				JAN 05, 1989

PENICILLAMINE

TABLET; ORAL

	DEPEN			
+	WALLACE	250MG		N19854 001
	DEPEN 250			
+	WALLACE	250MG		N19854 001

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM			
@	CONSOLIDATED PHARM	500,000 UNITS/VIAL		N60806 001
@		1,000,000 UNITS/VIAL		N60806 002
@		5,000,000 UNITS/VIAL		N60806 003
@		10,000,000 UNITS/VIAL		N60806 004
@	COPANOS	500,000 UNITS/VIAL		N60806 001
@		1,000,000 UNITS/VIAL		N60806 002
@		5,000,000 UNITS/VIAL		N60806 003
@		10,000,000 UNITS/VIAL		N60806 004
AP +	LILLY	**1,000,000 UNITS/VIAL**		**N60384 002**
AP +		**5,000,000 UNITS/VIAL**		**N60384 001**
AP +		**20,000,000 UNITS/VIAL**		**N60384 005**
AP		**20,000,000 UNITS/VIAL**		**N60601 001**
+		200,000 UNITS/VIAL		N60384 004
+		500,000 UNITS/VIAL		N60384 003

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM			
@	LILLY	200,000 UNITS/VIAL		N60384 004
@		500,000 UNITS/VIAL		N60384 003
@		1,000,000 UNITS/VIAL		N60384 002
@		5,000,000 UNITS/VIAL		N60384 001
@		20,000,000 UNITS/VIAL		N60384 005
@		20,000,000 UNITS/VIAL		N60601 001
	PFIZERPEN			
AP	PFIZER	**1,000,000 UNITS/VIAL**		**N60657 001**
AP +		**1,000,000 UNITS/VIAL**		**N60657 001**
AP		**5,000,000 UNITS/VIAL**		**N60657 002**
AP +		**5,000,000 UNITS/VIAL**		**N60657 002**
AP		**20,000,000 UNITS/VIAL**		**N60657 003**
AP +		**20,000,000 UNITS/VIAL**		**N60657 003**

TABLET; ORAL

	PENICILLIN G POTASSIUM			
AB	DISTA	**250,000 UNITS**		**N60403 001**
@	LILLY	250,000 UNITS		N60403 001

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	PENICILLIN G PROCAINE			
@	CONSOLIDATED PHARM	300,000 UNITS/ML		N60800 001
@		600,000 UNITS/1.2ML		N60800 002
@	COPANOS	300,000 UNITS/ML		N60800 001
@		600,000 UNITS/1.2ML		N60800 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	PENICILLIN V POTASSIUM			
AA	CONSOLIDATED PHARM	**EQ 125MG BASE/5ML**		**N61529 001**
AA		**EQ 250MG BASE/5ML**		**N61529 002**
AA	COPANOS	**EQ 125MG BASE/5ML**		**N61529 001**
AA		**EQ 250MG BASE/5ML**		**N61529 002**

TABLET; ORAL

	BETAPEN-VK			
AB	APOTHECON	**EQ 250MG BASE**		**N61411 001**
AB		**EQ 500MG BASE**		**N61411 002**
	PENICILLIN V POTASSIUM			
AB	CONSOLIDATED PHARM	**EQ 250MG BASE**		**N61528 001**

PENICILLIN V POTASSIUM

TABLET; ORAL
PENICILLIN V POTASSIUM

AB	CONSOLIDATED PHARM	EQ 500MG BASE	N61528 002
AB	COPANOS	EQ 250MG BASE	N61528 001
AB		EQ 500MG BASE	N61528 002

VEETIDS

AB	APOTHECON	EQ 250MG BASE	N61411 001
AB		EQ 500MG BASE	N61411 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTACARINAT

AP	ARMOUR	300MG/VIAL	N73447 001 APR 28, 1994
AP	RHONE POULENC RORER	300MG/VIAL	N73447 001 APR 28, 1994

PENTAMIDINE ISETHIONATE

AP	STERIS	300MG/VIAL	N74303 001 AUG 17, 1995

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	AMARIC	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
+		8MG	N20184 003 DEC 30, 1993
	JOHNSON RW	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
+		8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
MELFIAT-105

@ NUMARK	105MG	N87487 001 OCT 13, 1982

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
MELFIAT-105

@ SOLVAY	105MG	N87487 001 OCT 13, 1982

SPRX-105

@ NUMARK	105MG	N88024 001 DEC 22, 1982
@ SOLVAY	105MG	N88024 001 DEC 22, 1982

TABLET; ORAL
MELFIAT

@ NUMARK	35MG	N83790 002
@ SOLVAY	35MG	N83790 002

PHENDIMETRAZINE TARTRATE

@ NUMARK	35MG	N83790 001
@ SOLVAY	35MG	N83790 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	LEMMON	30MG	N87777 001 NOV 01, 1985
	@	30MG	N87777 001 NOV 01, 1985

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
IONAMIN

	FISONS	EQ 15MG BASE	N11613 004
+		EQ 30MG BASE	N11613 002

IONAMIN-15

FISONS	EQ 15MG BASE	N11613 004

IONAMIN-30

+ FISONS	EQ 30MG BASE	N11613 002

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC

+ LEO PHARM	12.5MG	N19456 001 DEC 28, 1989

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC

+	LEO PHARM	25MG	N19456 002	DEC 28, 1989
@		12.5MG	N19456 001	DEC 28, 1989
@		25MG	N19456 002	DEC 28, 1989

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	ROYCE LABS	5MG	N74437 001	FEB 27, 1995
AB		10MG	N74437 002	FEB 27, 1995

PIROXICAM

CAPSULE; ORAL
PIROXICAM

> ADD >	AB	ROYCE LABS	10MG	N74460 001 SEP 29, 1995
> ADD >	AB		20MG	N74460 002 SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

POWDER FOR RECONSTITUTION; ORAL
NULYTELY-FLAVORED

BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT	N19797 002	NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
COLYTE

> ADD >	AA	KREMERS URBAN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 010 JAN 31, 1989

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
COLYTE

> ADD >	AA	KREMERS URBAN	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 007 JUN 12, 1987
> DLT >	AA	REED AND CARNRICK	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 010 JAN 31, 1989
> DLT >	AA		240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 007 JUN 12, 1987

COLYTE-FLAVORED

> ADD >	AA	KREMERS URBAN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 008 NOV 14, 1991
> ADD >	AA		240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 009 NOV 14, 1991
> DLT >	AA	REED AND CARNRICK	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 008 NOV 14, 1991
> DLT >	AA		240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 009 NOV 14, 1991

GOLYTELY

AA	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N19011 002	JUN 02, 1992

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
MINIZIDE

PFIZER	0.5MG;1MG	N17986 001	
	0.5MG;2MG	N17986 002	
+	0.5MG;5MG	N17986 003	
	0.5MG;EQ 1MG BASE	N17986 001	
	0.5MG;EQ 2MG BASE	N17986 002	
+	0.5MG;EQ 5MG BASE	N17986 003	

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	AKORN	2MEQ/ML	N88286 001
			SEP 05, 1985
	@	2MEQ/ML	N88286 001
			SEP 05, 1985

TABLET, EXTENDED RELEASE; ORAL
KAON CL

	SAVAGE LABS	6.7MEQ	N17046 001
	@	6.7MEQ	N17046 001
	KAON CL-10		
BC	SAVAGE LABS	10MEQ	N17046 002
	@	10MEQ	N17046 002

PREDNISOLONE

TABLET; ORAL
CORTALONE

BX	HALSEY	1MG	N80304 003
BX		2.5MG	N80304 002
BX		5MG	N80304 001
	@	1MG	N80304 003
	@	2.5MG	N80304 002
	@	5MG	N80304 001
	PREDNISOLONE		
BX	SPERTI	1MG	N80358 001
		1MG	N80358 001

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS

AB	ALCON	1%	N17469 001
BX		1%	N17469 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL

AP	+ MERCK SHARP DOHME	EQ 20MG PHOSPHATE/ML	N11583 002
	+	EQ 20MG PHOSPHATE/ML	N11583 002
	PREDNISOLONE SODIUM PHOSPHATE		
AP	STERIS	EQ 20MG PHOSPHATE/ML	N80517 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
PREDNISOLONE SODIUM PHOSPHATE

	@ STERIS	EQ 20MG PHOSPHATE/ML	N80517 001

PREDNISONE

TABLET; ORAL
CORTAN

BX	HALSEY	20MG	N87480 001
	@	20MG	N87480 001

PROCAINAMIDE HYDROCHLORIDE

TABLET; ORAL
PRONESTYL

	APOTHECON	250MG	N17371 001
		375MG	N17371 002
	+	500MG	N17371 003
	SQUIBB	250MG	N17371 001
		375MG	N17371 002
	+	500MG	N17371 003

TABLET, EXTENDED RELEASE; ORAL
PROCAN SR

AB	PARKE DAVIS	250MG	N86468 001
	@	250MG	N86468 001
	PRONESTYL-SR		
BC	APOTHECON	500MG	N87361 001
BC	BRISTOL MYERS SQUIBB	500MG	N87361 001

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	AKORN	25MG/ML	N83955 002
AP		50MG/ML	N83955 001
	@	25MG/ML	N83955 002
	@	50MG/ML	N83955 001

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

AA	DANBURY PHARMA	15MG	N83029 002

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

	@	DANBURY PHARMA	15MG	N83029 002
AA		GLOBAL PHARMS	**15MG**	**N84541 002**
	@		15MG	N84541 002
AA		TABLICAPS	**15MG**	**N84428 001**
	@		15MG	N84428 001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPHTHAINE

AT	+	APOTHECON	**0.5%**	**N08883 001**
AT	+	SQUIBB	**0.5%**	**N08883 001**

> ADD >
> ADD >
> ADD >

PROPARACAINE HCL

AT		BAUSCH AND LOMB	**0.5%**	**N40074 001** SEP 29, 1995

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

AB		PARKE DAVIS	**20MG**	**N70439 001** SEP 15, 1986
AB			**40MG**	**N70440 001** SEP 15, 1986
AB			**60MG**	**N70441 001** SEP 24, 1986
AB			**80MG**	**N70442 001** SEP 15, 1986
AB		WARNER CHILCOTT	**10MG**	**N70438 001** SEP 15, 1986
	@		10MG	N70438 001 SEP 15, 1986
	@		20MG	N70439 001 SEP 15, 1986
	@		40MG	N70440 001 SEP 15, 1986
	@		60MG	N70441 001 SEP 24, 1986
	@		80MG	N70442 001 SEP 15, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD		LILLY	50MG	N06213 001
	@		50MG	N06213 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HCL

AB		SIDMAK LABS NJ	**5MG**	**N73644 001** AUG 24, 1995
AB			**10MG**	**N73645 001** AUG 24, 1995

VIVACTIL

AB		MERCK SHARP DOHME	**5MG**	**N16012 001**
AB	+		**10MG**	**N16012 002**

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HCL

AP		AKORN	**100MG/ML**	**N87967 001** OCT 01, 1982
	@		100MG/ML	N87967 001 OCT 01, 1982

QUINESTROL

TABLET; ORAL

ESTROVIS

	+	PARKE DAVIS	0.1MG	N16768 002
	@		0.1MG	N16768 002

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINALAN

BC		LANNETT	324MG	**N88081 001** FEB 10, 1986
	@		324MG	N88081 001 FEB 10, 1986

QUINIDINE SULFATE

TABLET; ORAL

	QUINIDINE SULFATE				
AB	**PHOENIX LABS NY**	**200MG**	**N83963 001**	>ADD<	
	@ VINTAGE PHARMS	200MG	N83963 001	>ADD<	
				>ADD<	

RAUWOLFIA SERPENTINA

TABLET; ORAL

>DLT<	**RAUDIXIN**				
>DLT<	BP **APOTHECON**	50MG	N08842 001		
>DLT<	BP +	100MG	N08842 002		
>ADD<	@	50MG	N08842 001		
>ADD<	@	100MG	N08842 002		
	RAUVAL				
>DLT<	BP **VALE**	100MG	N09108 004		
>ADD<	BP +	100MG	N09108 004		
	RAUWOLFIA SERPENTINA				
	BP **HALSEY**	50MG	N80498 001		
	BP	100MG	N80498 002		
	@	50MG	N80498 001		
	@	100MG	N80498 002		

RITODRINE HYDROCHLORIDE

TABLET; ORAL

>DLT<	**YUTOPAR**				
>DLT<	+ **ASTRA**	10MG	N18555 001	>ADD<	
>DLT<	@	10MG	N18555 001	>DLT<	
>ADD<				>DLT<	

SECOBARBITAL SODIUM

CAPSULE; ORAL

	SECOBARBITAL SODIUM				
AA	**ZENITH LABS**	**100MG**	**N85869 001**		
	@	100MG	N85869 001		

SEVOFLURANE

LIQUID; INHALATION

	ULTANE				
	ABBOTT	100%	N20478 001		
			JUN 07, 1995		

SILVER SULFADIAZINE

CREAM; TOPICAL

	SSD AF				
BX	KNOLL PHARM	1%			N18578 003
					JUL 11, 1990

SODIUM CHLORIDE

INJECTABLE; INJECTION

	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	**BAXTER**	**9MG/ML**			**N16677 004**
					OCT 30, 1985
AP	+	**9MG/ML**			**N16677 004**
					OCT 30, 1985

SOLUTION; IRRIGATION

	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AT	**BAXTER**	**450MG/100ML**			**N18497 001**
					FEB 19, 1982
	@	450MG/100ML			N18497 001
					FEB 19, 1982

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION

	CHROMITOPE SODIUM				
	BRACCO	200 uCi/ML		>ADD<	
	BRACCO DXS	250 uCi/VIAL	N13993 001	>DLT<	
		1mCi/VIAL	N13993 001	>DLT<	
			N13993 003		

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION

	BIO-TROPIN		
+	BIO TECH GEN	4.8MG/VIAL	N19774 001
			MAY 25, 1995
	GENOTROPIN		
+	PHARMACIA	1.5MG/VIAL	N20280 004
			AUG 24, 1995
+		5.8MG/VIAL	N20280 006
			AUG 24, 1995
	NORDITROPIN		
+	NOVO NORDISK	4MG/VIAL	N19721 001
			MAY 08, 1995

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
NORDITROPIN
+ NOVO NORDISK 8MG/VIAL N19721 002 MAY 08, 1995

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
BERLEX 120MG N19865 005 APR 20, 1994
@ 120MG N19865 005 APR 20, 1994

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE
AP LILLY **EQ 1GM BASE/VIAL** **N60107 001**
AP **EQ 5GM BASE/VIAL** **N60107 002**
EQ 1GM BASE/2ML N60404 001
@ EQ 1GM BASE/2ML N60404 001
@ EQ 1GM BASE/VIAL N60107 001
@ EQ 5GM BASE/VIAL N60107 002
AP + PFIZER **EQ 1GM BASE/VIAL** **N60076 001**
AP + **EQ 5GM BASE/VIAL** **N60076 002**
+ EQ 1GM BASE/VIAL N60076 001
+ EQ 5GM BASE/VIAL N60076 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN
AP APOTHECON **20MG/ML** **N08847 001**
@ 100MG/ML N08847 003 >ADD>
AP SQUIBB **20MG/ML** **N08847 001** >ADD>
@ 100MG/ML N08847 003 >ADD>

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA
AB BARRE **200MG/5ML;40MG/5ML** **N72289 001** MAY 23, 1988

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA
@ BARRE 200MG/5ML;40MG/5ML N72289 001 MAY 23, 1988

SULFUR

POWDER; TOPICAL
BENSULFOID
@ POYTHRESS 33.32% N02918 001

SUMATRIPTAN SUCCINATE

TABLET; ORAL
IMITREX
GLAXO WELLCOME EQ 25MG BASE N20132 002 JUN 01, 1995
+ EQ 50MG BASE N20132 003 JUN 01, 1995
@ EQ 100MG BASE N20132 001 JUN 01, 1995

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNELITE
DUPONT 0.0083-2.7 CI/GENERATOR N17771 001
TECHNETIUM TC 99M GENERATOR
DUPONT 0.0083-2.7 CI/GENERATOR **N17771 001**

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM
+ THERATECH 2.5MG/24HR N20489 001 SEP 29, 1995

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB PVT FORM **250MG** **N62686 001** JUL 24, 1986

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL		
AB	PVT FORM	**500MG**	**N62686 002**
			JUL 24, 1986
	@	250MG	N62686 001
			JUL 24, 1986
	@	500MG	N62686 002
			JUL 24, 1986

FIBER, EXTENDED RELEASE; PERIODONTAL

	ACTISITE		
	+ ON SITE	12.7MG/FIBER	N50653 001
			MAR 25, 1994
	+ ON SITE ALZA	12.7MG/FIBER	N50653 001
			MAR 25, 1994

OINTMENT; OPHTHALMIC

	ACHROMYCIN		
	+ LEDERLE	10MG/GM	N50266 001
	@ STORZ OPHTHALM	10MG/GM	N50266 001

SUSPENSION; ORAL

	ACHROMYCIN V		
AB	+ LEDERLE	**125MG/5ML**	**N50263 002**
	SUMYCIN		
AB	APOTHECON	**125MG/5ML**	**N60400 001**
	TETRACYCLINE HCL		
AB	BARRE	**125MG/5ML**	**N60633 001**
AB	MK LABS	**125MG/5ML**	**N60174 001**
	@ PROTER	125MG/5ML	N60446 001
AB	PUREPAC PHARM	**125MG/5ML**	**N60291 001**
	TETRACYN		
AB	PFIPHARMECS	**125MG/5ML**	**N60095 001**
	TETRAMED		
AB	ZENITH LABS	**125MG/5ML**	**N61468 001**

SUSPENSION/DROPS; OPHTHALMIC

	ACHROMYCIN		
	+ LEDERLE	1%	N50268 001
	@ STORZ OPHTHALM	1%	N50268 001

SYRUP; ORAL

	ACHROMYCIN V		
AB	+ LEDERLE	**125MG/5ML**	**N50263 002**
	SUMYCIN		
AB	SQUIBB	**125MG/5ML**	**N60400 001**
	TETRACYCLINE HCL		
AB	BARRE	**125MG/5ML**	**N60633 001**

TETRACYCLINE HYDROCHLORIDE

SYRUP; ORAL

	TETRACYCLINE HCL		
AB	MK LABS	**125MG/5ML**	**N60174 001**
AB	PUREPAC PHARM	**125MG/5ML**	**N60291 001**
	TETRACYN		
AB	PFIPHARMECS	**125MG/5ML**	**N60095 001**
	TETRAMED		
AB	ZENITH LABS	**125MG/5ML**	**N61468 001**

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	THEOPHYLLINE		
BC	FAULDING	100MG	N89976 001
			JAN 04, 1995
BC		200MG	N89977 001
			JAN 04, 1995
BC		300MG	N89932 001
			JAN 04, 1995

TABLET, EXTENDED RELEASE; ORAL

	LABID		
BC	+ PROCTER AND GAMBLE	250MG	N87225 001
	@	250MG	N87225 001
	THEOLAIR-SR		
BC	3M	250MG	N86363 002
			JUL 16, 1987
		250MG	N86363 002
			JUL 16, 1987
	THEOPHYLLINE		
AB	INWOOD LABS	**450MG**	**N40034 001**
			APR 28, 1995
	UNI-DUR		
BC	+ KEY PHARMS	400MG	N89822 001
			JAN 04, 1995
	+	600MG	N89823 001
			JAN 04, 1995
	UNIPHYL		
BC	PURDUE FREDERICK	400MG	N87571 001
			SEP 01, 1982

THEOPHYLLINE SODIUM GLYCINATE

TABLET; ORAL

	ASBRON		
	+ DORSEY	EQ 150MG BASE	N85148 001

THEOPHYLLINE SODIUM GLYCINATE

TABLET; ORAL
ASBRON
@ SANDOZ — EQ 150MG BASE — N85148 001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL
AP AKORN — **100MG/ML** — **N87968 001** — **OCT 01, 1982**
@ — 100MG/ML — N87968 001 — OCT 01, 1982

THIOTEPA

INJECTABLE; INJECTION
THIOPLEX
IMMUNEX — 15MG/VIAL — N20058 001 — DEC 22, 1994
AP LEDERLE — **15MG/VIAL** — **N20058 001** — **DEC 22, 1994**

THIOTEPA
AP + IMMUNEX — **15MG/VIAL** — **N11683 001**
\+ — 15MG/VIAL — N11683 001

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC
BETIMOL
\+ LEIRAS — EQ 0.25% BASE — N20439 001 — MAR 31, 1995
\+ — EQ 0.5% BASE — N20439 002 — MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE
AT ALCON — **EQ 0.25% BASE** — **N74261 001** — APR 28, 1995 — > ADD >
AT — **EQ 0.5% BASE** — **N74262 001** — APR 28, 1995 — > ADD > > DLT > > DLT >

TIMOPTIC
AT + MERCK — **EQ 0.25% BASE** — **N18086 001** — > DLT >

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOPTIC
AT + MERCK — **EQ 0.5% BASE** — **N18086 002**

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1
\+ BRISTOL MYERS — 6.5% — N19355 001 — DEC 30, 1986
\+ BRISTOL MYERS SQUIBB — 6.5% — N19355 001 — DEC 30, 1986

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL
TONOCARD
ASTRA MERCK — 400MG — N18257 001 — NOV 09, 1984
\+ — 600MG — N18257 002 — NOV 09, 1984
MERCK SHARP DOHME — 400MG — N18257 001 — NOV 09, 1984
\+ — 600MG — N18257 002 — NOV 09, 1984

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
ULTRAM
\+ JOHNSON RW — 50MG — N20281 002 — MAR 03, 1995
@ — 100MG — N20281 001 — MAR 03, 1995

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL
AB SIDMAK LABS NJ — **150MG** — **N71525 001** — MAR 09, 1988

TRAZON-150
AB SIDMAK LABS NJ — **150MG** — **N71525 001** — MAR 09, 1988

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
KENALOG-H
AT APOTHECON 0.1% N86240 001
AT WESTWOOD SQUIBB 0.1% N86240 001

INJECTABLE; INJECTION
KENALOG-10
+ APOTHECON 10MG/ML N12041 001
+ WESTWOOD SQUIBB 10MG/ML N12041 001
KENALOG-40
BP APOTHECON 40MG/ML N14901 001
BP WESTWOOD SQUIBB 40MG/ML N14901 001

LOTION; TOPICAL
KENALOG
AT APOTHECON 0.025% N84343 001
AT + 0.1% N84343 002
@ 0.025% N11602 003
@ 0.1% N11602 001
AT WESTWOOD SQUIBB 0.025% N84343 001
AT + 0.1% N84343 002
@ 0.025% N11602 003
@ 0.1% N11602 001
TRIAMCINOLONE ACETONIDE
AT BARRE 0.025% N87191 001 SEP 08, 1982
@ 0.025% N87191 001 SEP 08, 1982

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE IN ABSORBASE
+ CAROLINA MEDCL 0.05% N89595 001 MAR 23, 1995

PASTE; DENTAL
KENALOG IN ORABASE
AT + APOTHECON 0.1% N12097 001
AT + SQUIBB 0.1% N12097 001

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
ARISTOCORT
BP + LEDERLE 25MG/ML N11685 003
+ 25MG/ML N11685 003
TRIAMCINOLONE DIACETATE
BP AKORN 25MG/ML N85122 001

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
TRIAMCINOLONE DIACETATE
BP AKORN 40MG/ML N86394 001
@ 25MG/ML N85122 001
@ 40MG/ML N86394 001

TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUA
BP SCHERING 2MG N12265 001
@ 2MG N12265 001

TRILOSTANE

CAPSULE; ORAL
MODRASTANE
SANOFI WINTHROP 30MG N18719 002 DEC 31, 1984
+ 60MG N18719 001 DEC 31, 1984
@ 30MG N18719 002 DEC 31, 1984
@ 60MG N18719 001 DEC 31, 1984

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL
ASCENT EQ 25MG BASE/5ML N74374 001 JUN 23, 1995

TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
TRIPROLIDINE HCL
+ DANBURY PHARMA 2.5MG N85094 001
@ 2.5MG N85094 001

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL
TERFONYL
+ SQUIBB
@ 167MG/5ML;167MG/5ML; 167MG/5ML — N06904 002
167MG/5ML;167MG/5ML; 167MG/5ML — N06904 002

TABLET; ORAL
SULFA-TRIPLE #2
AB GLOBAL PHARMS — 167MG;167MG;167MG 167MG;167MG;167MG — N80079 001 N80079 001
AB + TERFONYL
AB + SQUIBB — 167MG;167MG;167MG — N06904 001
@ 167MG;167MG;167MG — N06904 001

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
AP + APOTHECON — 3MG/ML — N05657 001
AP + SQUIBB — 3MG/ML — N05657 001

UROFOLLITROPIN

INJECTABLE; INJECTION
METRODIN
> ADD > SERONO — 150 IU/AMP — N19415 003 SEP 18, 1986

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX
+ BURROUGHS WELLCOME — EQ 500MG BASE — N20487 001 JUN 23, 1995
@ EQ 1GM BASE — N20487 002 JUN 23, 1995

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID
AA HIGH TECH PHARMA — 250MG/5ML — N74060 001 JAN 13, 1995

VANCOMYCIN HYDROCHLORIDE

POWDER FOR RECONSTITUTION; ORAL
VANCOCIN HCL
AA LILLY — EQ 250MG BASE/5ML — N61667 002 JUL 13, 1983
AA + — EQ 500MG BASE/6ML — N61667 001
AB — EQ 250MG BASE/5ML — N61667 002 JUL 13, 1983
+ VANCOLED — EQ 500MG BASE/6ML — N61667 001
AA LEDERLE — EQ 250MG BASE/5ML — N63321 002 OCT 15, 1993
AA — EQ 500MG BASE/6ML — N63321 003 OCT 15, 1993
AB — EQ 250MG BASE/5ML — N63321 002 OCT 15, 1993
@ EQ 500MG BASE/6ML — N63321 003 OCT 15, 1993

VECURONIUM BROMIDE

INJECTABLE; INJECTION
NORCURON
AP + ORGANON — 10MG/VIAL — N18776 002 APR 30, 1984
AP + — 20MG/VIAL — N18776 003 JAN 03, 1992
VECURONIUM BROMIDE
AP STERIS — 10MG/VIAL — N74334 001 AUG 31, 1995
AP — 20MG/VIAL — N74334 002 AUG 31, 1995

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL
AP BEDFORD — 2.5MG/ML — N72888 001 JUL 28, 1995

VITAMIN A

CAPSULE; ORAL
VITAMIN A
AA BANNER PHARMACAPS — 50,000 USP UNITS — N83973 001

VITAMIN A

VITAMIN A

CAPSULE; ORAL
VITAMIN A
@ BANNER PHARMACAPS 50,000 USP UNITS N83973 001

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A
AA BANNER PHARMACAPS EQ 50,000 UNITS BASE N80702 001
@ EQ 50,000 UNITS BASE N80702 001
VITAMIN A PALMITATE
AA BANNER PHARMACAPS EQ 50,000 UNITS BASE N83948 001
@ EQ 50,000 UNITS BASE N83948 001

WARFARIN SODIUM

INJECTABLE; INJECTION
COUMADIN
+ DUPONT MERCK 5MG/VIAL N09218 024
FEB 07, 1995

WATER FOR INJECTION, STERILE

LIQUID; N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER
AP FUJISAWA 100% N89099 001
DEC 29, 1987
AP 100% N89100 001
DEC 29, 1987
@ 100% N89099 001
DEC 29, 1987
@ 100% N89100 001
DEC 29, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACETAMINOPHEN			
ABLE	120MG	N73106 001	> DLT >
		FEB 27, 1995	> ADD >
	325MG	N73107 001	> ADD >
		FEB 27, 1995	> DLT >
	650MG	N73108 001	> DLT >
		FEB 27, 1995	> ADD >

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A			> DLT >
+ CIBA	0.5%;0.05%	N18746 002	> ADD >
		JUL 11, 1994	> ADD >

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL

POLYSPORIN			> DLT >
@ BURROUGHS WELLCOME	10,000 UNITS/GM; 2,000,000 UNITS/GM	N50167 002	> DLT >
		MAR 01, 1985	> ADD >

> ADD > > ADD > > ADD > > ADD > > ADD >

CIMETIDINE

TABLET; ORAL

TAGAMET HB			> DLT >
+ SMITHKLINE BEECHAM	100MG	N20238 001	> ADD >
		JUN 19, 1995	> ADD >

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

ANTITUSSIVE			> DLT >
PERRIGO	12.5MG/5ML	N71292 001	> DLT >
		APR 10, 1987	> ADD >
@	12.5MG/5ML	N71292 001	> DLT >
		APR 10, 1987	> DLT >
BELDIN			> ADD >
HALSEY	12.5MG/5ML	N89179 001	> DLT >
		JUN 05, 1986	> ADD >
			> ADD >
			> DLT >
			> DLT >
			> DLT >
			> DLT >
			> DLT >
			> ADD >
			> ADD >
			> DLT >
			> DLT >
			> ADD >
			> ADD >

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

BELDIN		
@ HALSEY	12.5MG/5ML	N89179 001
		JUN 05, 1986
BENYLIN		
+ PARKE DAVIS	12.5MG/5ML	N06514 004
@	12.5MG/5ML	N06514 004
DIPHEN		
@ MORTON GROVE	12.5MG/5ML	N70118 001
		OCT 01, 1985
PENNEX	12.5MG/5ML	N70118 001
		OCT 01, 1985
DIPHENHYDRAMINE HCL		
CUMBERLAND SWAN	12.5MG/5ML	N73611 001
		AUG 20, 1992
@	12.5MG/5ML	N73611 001
		AUG 20, 1992
HI TECH PHARMA	12.5MG/5ML	N72416 001
		SEP 28, 1990
@	12.5MG/5ML	N72416 001
		SEP 28, 1990
HYDRAMINE		
BARRE	12.5MG/5ML	N70205 001
		JAN 28, 1986
@	12.5MG/5ML	N70205 001
		JAN 28, 1986
SILPHEN		
SILARX	12.5MG/5ML	N72646 001
		FEB 27, 1992
@	12.5MG/5ML	N72646 001
		FEB 27, 1992
VICKS FORMULA 44		
@ PROCTER AND GAMBLE	12.5MG/5ML	N70524 001
		JAN 14, 1987
VICKS HLTH CARE	12.5MG/5ML	N70524 001
		JAN 14, 1987

FAMOTIDINE

TABLET; ORAL

PEPCID AC		
+ MERCK	10MG	N20325 001
		APR 28, 1995

IBUPROFEN

CAPSULE; ORAL			
MIDOL			
+ WINTHROP	200MG	N70626 001	SEP 02, 1987
	200MG	N71002 001	SEP 02, 1987
@	200MG	N70626 001	SEP 02, 1987
@	200MG	N71002 001	SEP 02, 1987
PROVEL			
+ SANDOZ	200MG	N20402 001	APR 20, 1995
SUSPENSION; ORAL			
CHILDREN'S MOTRIN			
+ MCNEIL CONS PRODS	100MG/5ML	N20516 001	JUN 16, 1995
TABLET; ORAL			
MIDOL			
WINTHROP	200MG	N70591 001	SEP 02, 1987
	200MG	N71001 001	SEP 02, 1987
@	200MG	N70591 001	SEP 02, 1987
@	200MG	N71001 001	SEP 02, 1987

INSULIN PORK

INJECTABLE; INJECTION		
INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17926 003
REGULAR INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17926 003

INSULIN PURIFIED PORK

INJECTABLE; INJECTION		
VELOSULIN		
NOVO NORDISK	100 UNITS/ML	N18193 001
@	100 UNITS/ML	N18193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION		
INSULIN NORDISK MIXTARD (PORK)		
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N18195 001
@	30 UNITS/ML;70 UNITS/ML	N18195 001

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION		
MIXTARD HUMAN 70/30		
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19585 001 MAR 11, 1988
@	30 UNITS/ML;70 UNITS/ML	N19585 001 MAR 11, 1988
NOVOLIN 70/30		
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19441 001 JUL 11, 1986
@	30 UNITS/ML;70 UNITS/ML	N19441 001 JUL 11, 1986

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION		
NPH ILETIN II		
+ LILLY	100 UNITS/ML	N18479 001
@	100 UNITS/ML	N18479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION		
INSULIN INSULATARD NPH NORDISK		
+ NOVO NORDISK	100 UNITS/ML	N18194 001
@	100 UNITS/ML	N18194 001
NPH ILETIN II (PORK)		
@ LILLY	100 UNITS/ML	N18345 001
+	100 UNITS/ML	N18345 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION		
INSULATARD NPH HUMAN		
+ NOVO NORDISK	100 UNITS/ML	N19449 001 MAY 30, 1986

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
INSULATARD NPH HUMAN
@ NOVO NORDISK — 100 UNITS/ML — N19449 001 MAY 30, 1986

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF >ADD>

INJECTABLE; INJECTION >ADD>
PROTAMINE ZINC AND ILETIN II >ADD>
+ LILLY — 100 UNITS/ML — N18476 001 >ADD>
@ — 100 UNITS/ML — N18476 001 >ADD>
PROTAMINE ZINC INSULIN >ADD>
SQUIBB — 100 UNITS/ML — N17928 003
+ — 100 UNITS/ML — N17928 003

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
LEMMON — 1MG/5ML — N73478 001 JUN 23, 1995

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE
LEMMON — 2% — N74136 001 JAN 04, 1995

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
ABLE — 100MG — N73507 001 NOV 19, 1993
NMC — 100MG — N73507 001 NOV 19, 1993

NAPROXEN SODIUM

TABLET; ORAL
ALEVE
HAMILTON PHARMS — EQ 200MG BASE — N20204 002 JAN 11, 1994

NAPROXEN SODIUM

TABLET; ORAL
ALEVE
+ HAMILTON PHARMS — EQ 200MG BASE — N20204 002 JAN 11, 1994

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
NEOSPORIN
@ BURROUGHS WELLCOME — EQ 3.5MG BASE/GM; 10,000 UNITS/GM — N50176 002 JAN 14, 1985

NONOXYNOL-9

AEROSOL; VAGINAL
DELFEN
@ ORTHO — 12.5% — N14349 002

SPONGE; VAGINAL
TODAY
@ WHITEHALL LABS — 1GM — N18683 001 APR 01, 1983
@ WHITEHALL ROBINS — 1GM — N18683 001 APR 01, 1983

POTASSIUM IODIDE

SOLUTION; ORAL
POTASSIUM IODIDE
+ ROXANE — 1GM/ML — N18551 001 FEB 19, 1982
@ — 1GM/ML — N18551 001 FEB 19, 1982

PYRITHIONE ZINC

LOTION; TOPICAL
HEAD & SHOULDERS CONDITIONER
+ PROCTER AND GAMBLE — 0.3% — N19412 002 MAR 10, 1986
@ — 0.3% — N19412 002 MAR 10, 1986

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT 6GM/100ML;0.9GM/100ML N74193
JAN 30, 1995

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January - September, 1995]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ADENO-AS'TED VIRAL-BASED VECTOR CYSTIC FIBROSIS GENE THERAPY TN=	TREATMENT OF CYSTIC FIBROSIS.	TARGETED GENETICS CORPORATI 1100 OLIVE WAY, SUITE 100 SEATTLE WA 98101 DD 02/15/95 MA / /
ALGLUCERASE INJECTION TN= CEREDASE	REPLACEMENT THERAPY IN PATIENTS WITH TYPE II AND III GAUCHER'S DISEASE.	GENZYME CORPORATION ONE KENDALL SQUARE CAMBRIDGE MA 02139-1562 DD 07/21/95 MA / /
AMINOCAPROIC ACID TN=	FOR THE TOPICAL TREATMENT OF TRAUMATIC HYPHEMA OF THE EYE.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 01/06/95 MA / /
APL 400-020 TN=	TREATMENT OF CUTANEOUS T CELL LYMPHOMA.	APOLLON, INC. ONE GREAT VALLEY PARKWAY MALVERN PA 19355 DD 03/08/95 MA / /
APOMORPHINE HCL TN=	TREATMENT OF ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	PENTECH PHARMACEUTICALS, IN 417 HARVESTER COURT WHEELING IL 60090 DD 07/17/95 MA / /
BROMODEOXYURIDINE TN=	RADIATION SENSITIZER IN THE TREATMENT OF PRIMARY BRAIN TUMORS.	NEOPHARM, INC. 225 EAST DEERPATH, SUITE 25 LAKE FOREST IL 60045 DD 09/18/95 MA / /
CHONDROITINASE TN=	TREATMENT OF PATIENTS UNDERGOING VITRECTOMY.	STORZ OPHTHALMICS AMERICAN CYANAMID COMPANY PEARL RIVER NY 10965 DD 02/09/95 MA / /
CLOTRIMIDAZOLE TN=	TREATMENT OF SICKLE CELL DISEASE.	BRUGNARA, CARLO M.D. THE CHILDREN'S HOSPITAL BOSTON MA 02115 DD 04/24/95 MA / /
CYSTIC FIBROSIS TR GENE THERAPY (RECOMBINANT ADENOVIRUS) TN= ADgvCFTR.10	TREATMENT OF CYSTIC FIBROSIS.	GENVAC, INCORPORATED 12111 PARKLAWN DRIVE ROCKVILLE MD 20852 DD 03/09/95 MA / /
ELCATONIN TN=	INTRATHECAL TREATMENT OF INTRACTABLE PAIN.	INNAPHARMA,INCORPORATED 75 MONTEBELLO ROAD SUFFERN NY 10901 DD 09/25/95 MA / /
ENCAPSULATED PORCINE ISLET PREPARATION TN= BETARX	TREATMENT OF TYPE I DIABETIC PATIENTS WHO ARE ALREADY ON IMMUNOSUPPRESSION.	VIVORX 3212 NEBRASKA AVENUE SANTA MONICA CA 90404 DD 07/05/95 MA / /
FIBRINOGEN (HUMAN) TN=	FOR THE CONTROL OF BLEEDING AND PROPHYLACTIC TREATMENT OF PATIENTS DEFICIENT IN FIBRINOGEN.	ALPHA THERAPEUTIC CORPORATI 5555 VALLEY BOULEVARD LOS ANGELES CA 90032 DD 08/23/95 MA / /
FILGRASTIM TN= NEUPOGEN	FOR USE IN THE MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS FOR COLLECTION IN PATIENTS WHO WILL RECEIVE MYELOABLATIVE OR MYELOSUPPRESSIVE CHEMOTHERAPY.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 07/17/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
GABAPENTIN TN= NEURONTIN	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	WARNER-LAMBERT COMPANY PARKE-DAVIS PHARMACEUTICAL RESEARCH DIV. ANN ARBOR MI 48105-2430 DD 07/05/95 MA / /
GLUTAMINE TN=	FOR USE WITH HUMAN GROWTH HORMONE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
GLYCERYL TRIOLEATE AND GLYCERYL TRIERUCATE TN= LORENZO'S OIL	TREATMENT OF ADRENOLEUKODYSTROPHY.	MOSER, HUGO W. M.D. JOHNS HOPKINS UNIVERSITY BALTIMORE MD 21205 DD 02/14/95 MA / /
HEPATITIS B IMMUNE GLOBULIN, INTRAVENOUS TN= H-BIGIV	PROPHYLAXIS AGAINST HEPATITIS B VIRUS REINFECTION IN LIVER TRANSPLANT PATIENTS.	NORTH AMERICAN BIOLOGICS, INC. 16500 N.W. 15th AVENUE MIAMI FL 33169 DD 03/08/95 MA / /
HUMAN GROWTH HORMONE TN=	FOR USE WITH GLUTAMINE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
HUMAN IMMUNODEFICIENCY VIRUS IMMUNE GLOBULIN TN= HIVIG	TREATMENT OF HIV-INFECTED PEDIATRIC PATIENTS.	NORTH AMERICAN BIOLOGICALS, INC. 16500 N.W. 15TH AVENUE MIAMI FL 33169 DD 01/04/95 MA / /
INTRAVITREAL GANCICLOVIR FREE ACID IMPLANT TN= VITRASERT IMPLANT	TREATMENT OF CYTOMEGALOVIRUS RETINITIS.	CHIRON VISION 500 IOLAB DRIVE CLAREMONT CA 91711 DD 06/07/95 MA / /
KL4-SURFACTANT TN=	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN ADULTS.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 07/17/95 MA / /
LAMOTRIGINE TN= LAMICTAL	TREATMENT OF LENNOX-GASTAUT SYNDROME.	BURROUGHS-WELLCOME COMPANY 3030 CORNWALLIS ROAD, P.O. BOX 12700 RESEARCH TRIANGLE PK NC 27709 DD 08/23/95 MA / /
MITOLACTOL TN=	AS ADJUVANT THERAPY IN THE TREATMENT OF PRIMARY BRAIN TUMORS.	BIOPHARMACEUTICS, INC. 990 STATION ROAD BELLPORT NY 11713 DD 07/12/95 MA / /
NITRIC OXIDE TN=	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN ADULTS.	OHMEDA PHARMACEUTICAL PRODUCTS DIVISION 110 ALLEN ROAD LIBERTY CORNER NJ 07938-0804 DD 07/10/95 MA / /
NTBC TN=	TREATMENT OF TYROSINEMIA TYPE 1.	SWEDISH ORPHAN AB ORPHAN PHARMACEUTICAL, USA, INC. NASHVILLE TN 37217 DD 05/16/95 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
PHENYLALANINE AMMONIA-LYASE TN= PHENYLASE	TREATMENT OF HYPERPHENYLALANINEMIA.	IBEX TECHNOLOGIES, INC. 5485 PARE MONTREAL, QUEBEC DD 03/08/95 MA / /
PORFIROMYCIN TN=	TREATMENT OF HEAD AND NECK CANCER.	ONCORX INC. 4 SCIENCE PARK NEW HAVEN CT 06511 DD 09/19/95 MA / /
PURIFIED TYPE II COLLAGEN TN= COLLORAL	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	AUTOIMMUNE, INCORPORATED 128 SPRING STREET LEXINGTON MA 02173 DD 02/09/95 MA / /
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF ACUTE AND CHRONIC RESPIRATORY SYMPTOMS OF BRONCHIECTASIS.	BIOGEN, INCORPORATED 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 03/06/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF GROWTH HORMONE RECEPTOR DEFICIENCY.	PHARMACIA, INC. PO BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF ANTIBODY-MEDIATED GROWTH HORMONE RESISTANCE IN PATIENTS WITH ISOLATED GROWTH HORMONE DEFICIENCY IA.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RECOMBINANT METHIONYL HUMAN STEM CELL FACTOR TN=	FOR USE IN COMBINATION WITH FILGRASTIM TO DECREASE THE NUMBER OF PHERESES REQUIRED TO COLLECT PERIPHERAL BLOOD PROGENITOR CELLS CAPABLE OF PROVIDING RAPID MULTI-LINEAGE HEMATOPOIETIC RECONSTITUTION FOLLOWING MYELOSUPPRESSIVE OR MYELOABLATIVE THERAPY.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 07/05/95 MA / /
RGG0853, E1A LIPID COMPLEX TN=	TREATMENT OF ADVANCED OVARIAN CANCER THAT OVEREXPRESSES THE HER-2/neu ONCOGENE.	RGENE THERAPEUTICS, INC. 2170 BUCKTHORNE PLACE, SUITE 230 THE WOODLANDS TX 77380 DD 09/19/95 MA / /
RIFAPENTINE TN=	TREATMENT OF PULMONARY TUBERCULOSIS.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 94137 DD 06/09/95 MA / /
RIFAPENTINE TN=	TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 64137 DD 06/09/95 MA / /
SARGRAMOSTIM TN= LEUKINE	TO REDUCE NEUTROPENIA AND LEUKOPENIA AND DECREASE THE INCIDENCE OF DEATH DUE TO INFECTION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA.	IMMUNEX CORPORATION 51 UNIVERSITY STREET SEATTLE WA 98101 DD 03/06/95 MA / /
STERILE AEROSOL TALC TN=	TREATMENT OF MALIGNANT PLEURAL EFFUSION.	BRYAN CORPORATION 4 PLYMPTON STREET WOBURN MA 01801 DD 09/18/95 MA / /
SU-101 TN=	TREATMENT OF MALIGNANT GLIOMA.	SUGEN, INC. 515 GALVESTON DRIVE REDWOOD CITY CA 94063-4720 DD 05/25/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
SYNSORB PK TN=	TREATMENT OF VEROCYTOTOXOGENIC E. COLI INFECTIONS.	SYNSORB BIOTECH INC. FOURTH FLOOR, 140 4TH AVENUE SW CALGARY, ALBERTA DD 07/17/95 MA / /
THALIDOMIDE TN=	TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN SEVERLY, TERMINALLY IMMUNOCOMPROMISED PATIENTS.	CELGENE CORPORATION P.O. BOX 4914 WARREN NJ 07059 DD 05/01/95 MA / /
THALIDOMIDE TN=	TREATMENT AND PREVENTION OF RECURRENT APHTHOUS ULCERS IN SEVERLY, TERMINALLY IMMUNOCPOMPROMISED PATIENTS.	ANDRULIS RESEARCH CORPORATION 11800 BALTIMORE AVENUE, SUITE 113 BELTSVILLE MD 20705 DD 05/15/95 MA / /
THALIDOMIDE TN= SYNOVIR	TREATMENT OF ERYTHEMA NODOSUM LEPROSUM.	CELGENE CORPORATION 7 POWDER HORN DRIVE, PO BOX 4914 WARREN NJ 07059 DD 07/26/95 MA / /
TRISODIUM CITRATE CONCENTRATION TN= HEMOCITRATE	FOR USE IN LEUKAPHERESIS PROCEDURES.	HEMOTEC MEDICAL PRODUCTS, INC. BOX 19255 JOHNSTON RI 02919 DD 06/15/95 MA / /
TYLOXAPOL TN=	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs 50 NORTH MEDICAL DRIVE, U OF UTAH SALT LAKE CITY UT 84132 DD 03/08/95 MA / /

APPROVED ORPHAN PRODUCTS

AMIODARONE HCL TN= CORDARONE	FOR THE ACUTE TREATMENT AND PROPHYLAXIS OF LIFE-THREATENING VENTRICULAR TACHYCARDIA OR VENTRICULAR FIBRILLATION.	WYETH-AYERST LABORATORIES P.O. BOX 8299 PHILADELPHIA PA 19101-1245 DD 03/16/94 MA 08/03/95
DEXRAZOXANE TN= ZINECARD	FOR THE PREVENTION OF CARDIOMYOPATHY ASSOCIATED WITH DOXORUBICIN ADMINISTRATION.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 12/17/91 MA 05/26/95
Rho (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= WinRho SD	TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA.	RH PHARMACEUTICALS, INC. 104 CHANCELLOR MATHESON ROAD WINNIPEG, MANITOBA DD 11/09/93 MA 03/24/95

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 1995 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
CORTICOSTEROIDS, DERMATOLOGIC *IN VIVO* (TOPICAL)	JUN 02, 1995	
FLURBIPROFEN (TABLET)	DEC 24, 1992	JUN 08, 1995
NAPROXEN (TABLET)	JUN 12, 1992	JUN 08, 1995
TERFENADINE (TABLET)	JUN 12, 1992	SEP 11, 1995

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION
THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGEN REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUI ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE AN REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S D HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.				
REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FO SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.				
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 15MG	94 P-0212/ CP1	MIKART	NEW DOSAGE FORM
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 30MG	94 P-0211/ CP1	MIKART	NEW DOSAGE FORM
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 60MG	94 P-0210/ CP1	MIKART	NEW DOSAGE FORM
ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE TABLET; ORAL	712.8MG 60MG 32MG	93 P-0484/ CP1	MIKART	NEW DOSAGE FORM NEW STRENGTH
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET, CHEWABLE; ORAL	120MG 12MG	94 P-0182/ CP1	WE PHARMS	NEW DOSAGE FORM
ALBUTEROL SULFATE TABLET, CHEWABLE; ORAL	EQ 2MG BASE EQ 4MG BASE	92 P-0335/ CP1	WE PHARMS	NEW DOSAGE FORM
ATRACURIUM BESYLATE INJECTABLE; INJECTION	25MG/ML	94 P-0314/ CP1	ABBOTT	NEW STRENGTH
CALCITONIN, SALMON INJECTABLE; INJECTION	100 IU/ML (0.5ML/AMP) 1ML/AMP)	95 P-0080/ CP1	FERRING	NEW STRENGTH
CAPTOPRIL SOLUTION; ORAL	25MG/ML	95 P-0008/ CP1	ROXANE	NEW DOSAGE FORM NEW STRENGTH
FLUOROURACIL GEL; TOPICAL	5%	94 P-0263/ CP1	BRADLEY PHARMS	NEW DOSAGE FORM
IOPAMIDOL INJECTABLE; INJECTION	61% (250ML/CONTAINER) (500ML/CONTAINER)	95 P-0073/ CP1	ABBOTT	NEW STRENGTH
IOPAMIDOL INJECTABLE; INJECTION	76% (250ML/CONTAINER) (500ML/CONTAINER)	95 P-0073/ CP1	ABBOTT	NEW STRENGTH
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (5ML/VIAL)	94 P-0433/ CP2	LEDERLE	NEW DOSAGE FORM
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (20ML/VIAL)	94 P-0433/ CP3	LEDERLE	NEW DOSAGE FORM NEW STRENGTH

STATUS

CY HAS DETERMINED THAT THE
TABLE FOR SUBMISSION AS AN
DA ITSELF IS SUBMITTED AND
OCKETS MANAGEMENT BRANCH,

R A FULL LISTING OF ANDA

APPROVED
JAN 19, 1995

APPROVED
JAN 19, 1995

APPROVED
JAN 19, 1995

APPROVED
JAN 19, 1995

APPROVED
JAN 19, 1995

APPROVED
JAN 19, 1995

APPROVED
MAY 02, 1995

APPROVED
AUG 07, 1995

APPROVED
AUG 07, 1995

APPROVED
SEP 12, 1995

APPROVED
AUG 23, 1995

APPROVED
AUG 23, 1995

APPROVED
AUG 07, 1995

APPROVED
AUG 07, 1995

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (35ML/VIAL)	94 P-0433/ CP1	LEDERLE	NEW DOSAGE FORM	APPROVED AUG 07, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (100MG/VIAL)	93 P-0427/ CP3	ABBOTT	NEW DOSAGE FORM	APPROVED JAN 19, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (250MG/VIAL)	93 P-0427/ CP2	ABBOTT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
LORAZEPAM SOLUTION; ORAL	0.5MG/5ML	94 P-0199/ CP1	ROXANE	NEW DOSAGE FORM	APPROVED FEB 07, 1995
MEDROXYPROGESTERONE ACETATE TABLET; ORAL	2MG 4MG 8MG	92 P-0452/ CP1	CARNRICK	NEW STRENGTH	APPROVED AUG 07, 1995
METHYLPREDNISOLONE TABLET, CHEWABLE; ORAL	4MG 16MG 24MG 32MG	94 P-0432/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED AUG 07, 1995
SULFAMETHOXAZOLE; TRIMETHOPRIM TABLET, CHEWABLE; ORAL	200MG 40MG	94 P-0186/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
THIORIDAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0283/ CP1	UDL LABS	NEW STRENGTH	APPROVED JAN 19, 1995

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROMORPHONE HYDROCHLORIDE INJECTABLE; INJECTION	0.2MG/ML (50ML PREFILLED SYRINGE)	95 P-0022/ CP1	ASTRA	NEW INDICATION NEW ROUTE OF ADMINISTRATION NEW STRENGTH	DENIED SEP 07, 1995
MEFLOQUINE HYDROCHLORIDE TABLET; ORAL	275MG	94 P-0329/ CP1	LACASSE	NEW DOSING REGIMEN NEW STRENGTH	DENIED SEP 07, 1995
NICOTINE POLACRILEX LOLLIPOP; ORAL	2MG	93 P-0414/ CP1	SAVAGE	NEW DOSAGE FORM	DENIED MAY 02, 1995
NORETHINDRONE ACETATE TABLET; ORAL	1MG 2.5MG	94 P-0446/ CP1	APOTHECON	NEW INGREDIENT NEW STRENGTH	DENIED SEP 07, 1995
SELEGILINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL	10MG	94 P-0387/ CP1	PHARMAVENE	NEW DOSAGE FORM NEW STRENGTH	DENIED MAY 08, 1995
TERFENADINE TABLET, CHEWABLE; ORAL	60MG	94 P-0119/ CP1	DURA PHARMS	NEW DOSAGE FORM	DENIED AUG 23, 1995

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-26 ONCE WEEKLY APPLICATION

D-27 BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY

D-28 USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300

REFERENCES

NEW INDICATION

I-117 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE

I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY

I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY

I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS

I-121 EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS

I-122 PSORIASIS OF THE SCALP

I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER

I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE

I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES

I-126 ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY

I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS

I-128 IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB)

I-129 TREATMENT OF ALCOHOL DEPENDENCE

I-130 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS

I-131 PERIPHERAL ARTERIOGRAPHY

I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER

I-133 MANAGEMENT OF CHRONIC STABLE ANGINA

I-134 HEART FAILURE POST MYOCARDIAL INFARCTION

I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA

REFERENCES

PATENT USE CODE

U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

U-103 TREATMENT OF OCULAR HYPERTENSION

U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

U-105 EMESIS

U-106 TREATMENT OF EPILEPSY

U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS

U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGICAL HYPERSECRETORY CONDITIONS

EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-109	USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMA HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOU OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
						NCE	SEP 06, 2000
>ADD>	20482 001	ACARBOSE; PRECOSE				NCE	SEP 06, 2000
>ADD>	20482 002	ACARBOSE; PRECOSE					
	19872 001	ACETAMINOPHEN; TYLENOL	5004613	JUL 27, 2007			
			4968509	NOV 06, 2007			
			4820522	JUL 27, 2007		NDF	JUN 08, 1997
	19806 001	ACRIVASTINE; SEMPREX-D	4501893	FEB 01, 2003			
	20059 001	ADENOSINE; ADENOSCAN				I-126	MAY 18, 1998
	19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	4353365	APR 24, 1998			
			4206758	APR 24, 1998			
	18702 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4124707	DEC 12, 1996			
	18707 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4124707	DEC 12, 1996			
>ADD>	20560 001	ALENDRONATE SODIUM; FOSAMAX	5358941	DEC 02, 2012			
>ADD>			4621077	NOV 04, 2003	U-114	NCE	SEP 29, 2000
>ADD>	20560 002	ALENDRONATE SODIUM; FOSAMAX	5358941	DEC 02, 2012			
>ADD>			4621077	NOV 04, 2003	U-114	NCE	SEP 29, 2000
						NP	JUL 06, 1998
	20379 001	ALPROSTADIL; CAVERJECT				NP	JUL 06, 1998
	20379 002	ALPROSTADIL; CAVERJECT				ODE	AUG 03, 2002
	20377 001	AMIODARONE HYDROCHLORIDE; CORDARONE				NDF	AUG 03, 1998
			4879303	MAR 25, 2007			
	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		NC	MAR 03, 1998
	20364 002	AMLODIPINE BESYLATE; LOTREL	4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
	20364 003	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
	20364 004	AMLODIPINE BESYLATE; LOTREL	4410520	OCT 18, 2002		NCE	JUL 31, 1997
			4879303	MAR 25, 2007		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
	20259 001	ATOVAQUONE; MEPRON	4410520	OCT 18, 2002		NCE	JUL 31, 1997
	20500 001	ATOVAQUONE; MEPRON	4981874	AUG 15, 2009	U-69		
			5053432	OCT 01, 2008		NCE	NOV 25, 1997
			4981874	AUG 15, 2009	U-69	NDF	FEB 08, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18644 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			
	18644 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			
	18644 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			
>ADD>	19215 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	JUL 28, 1997			
>DLT>	~~19215 001~~	~~BUTOCONAZOLE NITRATE; FEMSTAT~~	~~4078071~~	~~MAR 07, 1997~~			
>ADD>	19359 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	JUL 28, 1997			
>DLT>	~~19359 001~~	~~BUTOCONAZOLE NITRATE; FEMSTAT~~	~~4078071~~	~~MAR 07, 1997~~			
	20313 002	CALCITONIN, SALMON; MIACALCIN				NDF	AUG 17, 1998
	18343 001	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 002	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 003	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 005	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 006	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18709 001	CAPTOPRIL; CAPOZIDE 25/15	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 002	CAPTOPRIL; CAPOZIDE 25/25	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 003	CAPTOPRIL; CAPOZIDE 50/25	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 004	CAPTOPRIL; CAPOZIDE 50/15	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19856 001	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
			4832957	JUN 16, 2006			
	19856 002	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
			4832957	JUN 16, 2006			
						NCE	SEP 14, 2000
>ADD>	20297 001	CARVEDILOL; COREG				NCE	SEP 14, 2000
>ADD>	20297 002	CARVEDILOL; COREG				NCE	SEP 14, 2000
>ADD>	20297 003	CARVEDILOL; COREG					
	20044 001	CETYL ALCOHOL; EXOSURF NEONATAL	5110806	MAY 02, 2006			
			4312860	NOV 21, 2001			
	18663 001	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			
	18663 002	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			
	20238 001	CIMETIDINE; TAGAMET HB				NS	JUN 19, 1998
>ADD>	19847 001	CIPROFLOXACIN; CIPRO	4670444	DEC 09, 2003			
>DLT>	~~19847 001~~	~~CIPROFLOXACIN; CIPRO~~	~~4670444~~	~~OCT 01, 2003~~			
>ADD>	19857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4670444	DEC 09, 2003			
>DLT>	~~19857 001~~	~~CIPROFLOXACIN; CIPRO IN DEXTROSE 5%~~	~~4670444~~	~~OCT 01, 2003~~			
>ADD>	19858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4670444	DEC 09, 2003			
>DLT>	~~19858 001~~	~~CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%~~	~~4670444~~	~~OCT 01, 2003~~			
>ADD>	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
>ADD>			4670444	DEC 09, 2003	U-36		
>DLT>			~~4670444~~	~~OCT 01, 2002~~	~~U-36~~		
>ADD>	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
>ADD>			4670444	DEC 09, 2003	U-36		
>DLT>			~~4670444~~	~~OCT 01, 2002~~	~~U-36~~		
>ADD>	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
>ADD>			4670444	DEC 09, 2003	U-36		
>DLT>			~~4670444~~	~~OCT 01, 2002~~	~~U-36~~		
						NCE	JUL 29, 1998
>ADD>	20398 001	CISAPRIDE MONOHYDRATE; PROPULSID	4559222	MAY 04, 2003			
	18891 001	CLONIDINE; CATAPRES-TTS-1	4201211	JUL 12, 1997			
	18891 002	CLONIDINE; CATAPRES-TTS-2	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
	18891 003	CLONIDINE; CATAPRES-TTS-3	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
						NDF	JUL 19, 1997
	20222 001	COLESTIPOL HYDROCHLORIDE; COLESTID	4537883	NOV 12, 2002			
	12142 006	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 007	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	12142 008	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN					
	12142 009	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN					
	12142 010	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN					
	20287 001	DALTEPARIN SODIUM; FRAGMIN	4537883	NOV 12, 2002			
	19849 001	DAPIPRAZOLE HYDROCHLORIDE; REV-EYES	4537883	NOV 12, 2002			
	20212 001	DEXRAZOXANE HYDROCHLORIDE; ZINECARD	4537883	NOV 12, 2002			
			4303651	JAN 04, 2000		NCE	DEC 22, 1999
	20212 002	DEXRAZOXANE HYDROCHLORIDE; ZINECARD	4252721	FEB 07, 2003			
						NCE	MAY 26, 2000
						ODE	MAY 26, 2002
	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD				NCE	MAY 26, 2000
	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD				ODE	MAY 26, 2002
	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD					
	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD					
	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5286497	MAY 20, 2011			
	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5286497	MAY 20, 2011			
	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5286497	MAY 20, 2011			
	20411 001	DINOPROSTONE; CERVIDIL	5286497	MAY 20, 2011			
			4839177	DEC 09, 2006		I-133	OCT 15, 1995
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	4839177	DEC 09, 2006		I-133	OCT 15, 1995
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	4839177	DEC 09, 2006		I-133	OCT 15, 1995
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	5269321	DEC 14, 2010	U-110		
	20408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4931288	JAN 16, 2007		NDF	MAR 30, 1998
			4988731	JAN 29, 2008		I-132	MAY 26, 1998
	19946 001	DOXACURIUM CHLORIDE; NUROMAX	4988731	JAN 29, 2008		I-132	MAY 26, 1998
	19668 001	DOXAZOSIN MESYLATE; CARDURA	4988731	JAN 29, 2008		I-132	MAY 26, 1998
	19668 002	DOXAZOSIN MESYLATE; CARDURA	4797413	JUN 30, 2004	U-103	NCE	DEC 09, 1999
	19668 003	DOXAZOSIN MESYLATE; CARDURA	4619939	OCT 28, 2003	U-104		
	19668 004	DOXAZOSIN MESYLATE; CARDURA				I-121	DEC 08, 1997
	20126 001	DOXEPIN HYDROCHLORIDE; ZONALON				I-96	FEB 06, 1998
	19221 003	ENALAPRIL MALEATE; VASERETIC				I-96	FEB 06, 1998
						I-96	FEB 06, 1998
	19616 004	ENOXACIN; PENETREX				I-96	FEB 06, 1998
	19616 005	ENOXACIN; PENETREX	4395420	DEC 09, 2001	U-95		
	20164 001	ENOXAPARIN SODIUM; LOVENOX	4472380	SEP 18, 2001			
>ADD>	20444 001	EPOPROSTENOL SODIUM; FLOLAN	4374829	FEB 22, 2000		NS	JUL 12, 1998
>ADD>	20444 002	EPOPROSTENOL SODIUM; FLOLAN	4442101	FEB 04, 2002			
	18418 001	ERGOLOID MESYLATES; HYDERGINE	4442101	FEB 04, 2002			
						I-118	MAR 09, 1998
						NCE	SEP 20, 2000
			4138565	MAY 26, 1996		NCE	SEP 20, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
18706 001	ERGOLOID MESYLATES; HYDERGINE LC					
19081 002	ESTRADIOL; ESTRADERM	4366145	JUN 24, 2001			
19081 003	ESTRADIOL; ESTRADERM	4379454	FEB 17, 2001			
20323 001	ESTRADIOL; VIVELLE	4379454	FEB 17, 2001			
		5300291	APR 05, 2011		NS	OCT 28, 1997
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20323 002	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20323 003	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20323 004	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20375 001	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
20375 002	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
86069 001	ESTRADIOL; ESTRACE	4436738	MAR 15, 2002			
20303 001	ESTROGENS, CONJUGATED; PREMPRO (PREMARIN;CYCRIN 14/14)	4826831	MAY 02, 2006	U-102	NP	DEC 30, 1997
18977 001	ETHINYL ESTRADIOL; TRI-NORINYL 21-DAY	4390531	AUG 10, 2001			
18977 002	ETHINYL ESTRADIOL; TRI-NORINYL 28-DAY	4390531	AUG 10, 2001			
18985 001	ETHINYL ESTRADIOL; ORTHO-NOVUM 7/7/7-21	4628051	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4530839	SEP 26, 2003			
18985 002	ETHINYL ESTRADIOL; ORTHO-NOVUM 7/7/7-28	4628051	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4530839	SEP 26, 2003			
19697 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003			
		4544554	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19697 002	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	SEP 26, 2003	U-66		
			4616006	SEP 26, 2003			
			4544554	SEP 26, 2003	U-66		
			4530839	SEP 26, 2003	U-112		
>ADD>	19462 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
>DLT>	~~19462 001~~	~~FAMOTIDINE; PEPCID~~	~~4283408~~	~~AUG 11, 2000~~			
>ADD>	19462 002	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
>DLT>	~~19462 002~~	~~FAMOTIDINE; PEPCID~~	~~4283408~~	~~AUG 11, 2000~~			
>ADD>	19510 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
>DLT>	~~19510 001~~	~~FAMOTIDINE; PEPCID~~	~~4283408~~	~~AUG 11, 2000~~			
>ADD>	19527 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
>DLT>	~~19527 001~~	~~FAMOTIDINE; PEPCID~~	~~4283408~~	~~AUG 11, 2000~~			
>ADD>	20249 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
>DLT>	~~20249 001~~	~~FAMOTIDINE; PEPCID~~	~~4283408~~	~~AUG 11, 2000~~			
>ADD>	20325 001	FAMOTIDINE; PEPCID AC	4283408	OCT 15, 2000		NS	APR 28, 1998
>DLT>	~~20325 001~~	~~FAMOTIDINE; PEPCID AC~~	~~4283408~~	~~AUG 11, 2000~~		~~NS~~	~~APR 28, 1998~~
>ADD>	20189 001	FELBAMATE; FELBATOL	5082861	SEP 26, 2009	U-83		
>DLT>	~~20189 001~~	~~FELBAMATE; FELBATOL~~	~~5082861~~	~~DEC 07, 2010~~	~~U-83~~		
			4978680	SEP 26, 2009	U-83		
>ADD>	20189 002	FELBAMATE; FELBATOL	5082861	SEP 26, 2009	U-83		
>DLT>	~~20189 002~~	~~FELBAMATE; FELBATOL~~	~~5082861~~	~~DEC 07, 2010~~	~~U-83~~		
			4978680	SEP 26, 2009	U-83		
>ADD>	20189 003	FELBAMATE; FELBATOL	5082861	SEP 26, 2009	U-83		
>DLT>	~~20189 003~~	~~FELBAMATE; FELBATOL~~	~~5082861~~	~~DEC 07, 2010~~	~~U-83~~		
			4978680	SEP 26, 2009	U-83		
	19834 001	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
			4264611	APR 28, 2000	U-3	NCE	JUL 25, 1996
	19834 002	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
			4264611	APR 28, 2000	U-3	NCE	JUL 25, 1996
	19834 004	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
			4264611	APR 28, 2000	U-3	NCE	JUL 25, 1996
	19813 001	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
	19813 002	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
	19813 003	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
	19813 004	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
	19960 001	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
	19960 002	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19960 003	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
	19960 004	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
	19949 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
	19949 002	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
	19949 003	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
	19950 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
	20090 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
	20090 002	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
	20322 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
>ADD>	20073 001	FLUMAZENIL; ROMAZICON	4316839	OCT 10, 2004			
>DLT>	~~20073 001~~	~~FLUMAZENIL; ROMAZICON~~	~~4316839~~	~~MAR 02, 2003~~			
	18148 001	FLUNISOLIDE; NASALIDE	4933168	JUN 12, 2007			
	18340 001	FLUNISOLIDE; AEROBID	4933168	JUN 12, 2007			
	20409 001	FLUNISOLIDE; NASAREL	4983595	MAY 22, 2006			
			4933168	JUN 12, 2007			
			4782047	MAY 22, 2006			
	19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTHE/FS				I-122	FEB 16, 1998
	19957 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 15, 2002			
	19958 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 15, 2002			
	20121 001	FLUTICASONE PROPIONATE; FLONASE	4335121	MAR 15, 2002		NCE	DEC 14, 1995
						NDF	OCT 19, 1997
	20261 001	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
	20261 002	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4339445	JUL 29, 1997	U-64	I-127	JUN 16, 1998
	19915 002	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000		I-92	MAY 02, 1998
	19915 003	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000		I-92	MAY 02, 1998
	19915 004	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000		I-92	MAY 02, 1998
			4337201	JUN 29, 2001		NCE	MAY 16, 1996
	20286 001	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000			
	20286 002	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000			
	20235 001	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
	20235 002	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20235 003	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	5362475	NOV 08, 2011			
	20460 001	GANCICLOVIR; CYTOVENE	4507305	OCT 19, 1999	U-64	NDF	DEC 22, 1997
>ADD>			4355032	JUN 23, 2003	U-64		
>DLT>			~~4355032~~	~~MAR 16, 2003~~	~~U-64~~		
	19661 001	GANCICLOVIR SODIUM; CYTOVENE	4507305	MAY 21, 2001	U-35		
			4423050	MAY 21, 2001	U-34		
>ADD>			4355032	JUN 23, 2003	U-64		
>DLT>			~~4355032~~	~~MAR 16, 2003~~	~~U-64~~		
	20329 001	GLIPIZIDE; GLUCOTROL XL	5091190	JUN 18, 2008	U-111		
			5082668	SEP 16, 2003			
			5024843	SEP 05, 2009			
			4612008	SEP 16, 2003			
			4327725	NOV 25, 2000		NDF	APR 26, 1997
	20329 002	GLIPIZIDE; GLUCOTROL XL	5091190	JUN 18, 2008	U-111		
			5082668	SEP 16, 2003			
			5024843	SEP 05, 2009			
			4612008	SEP 16, 2003			
			4327725	NOV 25, 2000		NDF	APR 26, 1997
>ADD>	19726 001	GOSERELIN ACETATE; ZOLADEX	4100274	APR 22, 1999			
>DLT>	~~19726 001~~	~~GOSERELIN ACETATE; ZOLADEX~~	~~4100274~~	~~JUL 10, 1997~~			
	20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 12, 2006	U-105	NCE	DEC 29, 1998
						NDF	MAR 16, 1998
	19059 001	HYDROCHLOROTHIAZIDE; INDERIDE LA 80/50	4138475	SEP 14, 1997			
	19059 002	HYDROCHLOROTHIAZIDE; INDERIDE LA 120/50	4138475	SEP 14, 1997			
	19059 003	HYDROCHLOROTHIAZIDE; INDERIDE LA 160/50	4138475	SEP 14, 1997			
	19129 001	HYDROCHLOROTHIAZIDE; MAXZIDE	4444769	JUL 27, 2002			
	19129 003	HYDROCHLOROTHIAZIDE; MAXZIDE-25	4444769	JUL 27, 2002			
	20387 001	HYDROCHLOROTHIAZIDE; HYZAAR	5153197	OCT 06, 2009	U-3	NC	APR 28, 1998
			5138069	AUG 11, 2009		NCE	APR 14, 2000
	19842 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		I-123	MAR 24, 1998
	20135 001	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
			5215755	JUN 01, 2010		NDF	NOV 16, 1997
	20135 002	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
			5215755	JUN 01, 2010		NDF	NOV 16, 1997
	20418 001	IBUPROFEN; MOTRIN				I-123	MAR 24, 1998
	20516 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18185 001	INDOMETHACIN; INDOCIN SR	4173626	DEC 11, 1998			
	20084 001	IOBENGUANE SULFATE I 131; IOBENGUANE SULFATE I 131				ODE	MAR 25, 2001
	18956 007	IOHEXOL; OMNIPAQUE 70	4396597	JUL 14, 1998			
			4250113	DEC 26, 1999			
>ADD>	18735 001	IOPAMIDOL; ISOVUE-M 200	4001323	NOV 24, 1997			
>DLT>	~~18735 001~~	~~IOPAMIDOL; ISOVUE-M 200~~	~~4001323~~	~~JAN 04, 1996~~			
>ADD>	18735 002	IOPAMIDOL; ISOVUE-300	4001323	NOV 24, 1997			
>DLT>	~~18735 002~~	~~IOPAMIDOL; ISOVUE-300~~	~~4001323~~	~~JAN 04, 1996~~			
>ADD>	18735 003	IOPAMIDOL; ISOVUE-370	4001323	NOV 24, 1997		D-28	MAY 15, 1998
>DLT>	~~18735 003~~	~~IOPAMIDOL; ISOVUE-370~~	~~4001323~~	~~JAN 04, 1996~~			
>ADD>	18735 004	IOPAMIDOL; ISOVUE-M 300	4001323	NOV 24, 1997			
>DLT>	~~18735 004~~	~~IOPAMIDOL; ISOVUE-M 300~~	~~4001323~~	~~JAN 04, 1996~~		~~D-28~~	~~MAY 15, 1998~~
>ADD>	18735 007	IOPAMIDOL; ISOVUE-250	4001323	NOV 24, 1997			
>DLT>	~~18735 007~~	~~IOPAMIDOL; ISOVUE-250~~	~~4001323~~	~~JAN 04, 1996~~			
>ADD>	20327 001	IOPAMIDOL; ISOVUE-200	4001323	NOV 24, 1997			
>DLT>	~~20327 001~~	~~IOPAMIDOL; ISOVUE-200~~	~~4001323~~	~~JAN 04, 1996~~			
>ADD>	20327 002	IOPAMIDOL; ISOVUE-250	4001323	NOV 24, 1997			
>DLT>	~~20327 002~~	~~IOPAMIDOL; ISOVUE-250~~	~~4001323~~	~~JAN 04, 1996~~			
>ADD>	20327 003	IOPAMIDOL; ISOVUE-300	4001323	NOV 24, 1997			
>DLT>	~~20327 003~~	~~IOPAMIDOL; ISOVUE-300~~	~~4001323~~	~~JAN 04, 1996~~			
>ADD>	20327 004	IOPAMIDOL; ISOVUE-370	4001323	NOV 24, 1997			
>DLT>	~~20327 004~~	~~IOPAMIDOL; ISOVUE-370~~	~~4001323~~	~~JAN 04, 1996~~			
	20220 001	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
	20220 002	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
	20220 003	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
	20220 004	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
	19710 005	IOVERSOL; OPTIRAY 350				I-131	JUN 21, 1998
	20225 003	ISOSORBIDE MONONITRATE; IMDUR				NDF	AUG 12, 1996
						NCE	DEC 30, 1996
	20336 001	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
	20336 002	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
	19816 002	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	19816 003	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
>ADD>	19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	JUL 14, 1998	U-55		
>DLT>	~~19645 001~~	~~KETOROLAC TROMETHAMINE; TORADOL~~	~~4089969~~	~~MAY 16, 1997~~	~~U-55~~		
>ADD>	19698 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	JUL 14, 1998	U-55	NR	DEC 07, 1997
>DLT>	~~19698 001~~	~~KETOROLAC TROMETHAMINE; TORADOL~~	~~4089969~~	~~MAY 16, 1997~~	~~U-55~~	~~NR~~	~~DEC 07, 1997~~

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19698 002	KETOROLAC TROMETHAMINE; TORADOL	4089969	JUL 14, 1998	U-55	NR	DEC 07, 1997
>DLT>	~~19698 002~~	~~KETOROLAC TROMETHAMINE; TORADOL~~	~~4089969~~	~~MAY 16, 1997~~	~~U-55~~	~~NR~~	~~DEC 07, 1997~~
	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4454151	MAR 22, 2002	U-75		
>ADD>			4089969	JUL 14, 1998	U-55		
>DLT>			~~4089969~~	~~MAY 16, 1997~~	~~U-55~~		
	18686 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4328213	NOV 28, 1999			
	20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20406 001	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
			5045321	SEP 03, 2008			
			5026560	JUN 25, 2008			
			4689333	JUL 29, 2005			
			4628098	JUL 29, 2005		NCE	MAY 10, 2000
	20406 002	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
			5045321	SEP 03, 2008			
			5026560	JUN 25, 2008			
			4689333	JUL 29, 2005			
			4628098	JUL 29, 2005		NCE	MAY 10, 2000
	19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
			4005063	JAN 25, 1996		I-119	MAR 30, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20263 001	LEUPROLIDE ACETATE; LUPRON	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
	20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
	20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
	20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
	20263 005	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
>ADD>			4849228	JUL 18, 2006			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
>ADD>			4005063	JAN 25, 1996			
	20263 006	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
>ADD>			4849228	JUL 18, 2006			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
>ADD>			4005063	JAN 25, 1996			
	18027 001	LITHIUM CARBONATE; LITHOBID	4264573	MAY 21, 1999			
>ADD>	19658 001	LORATADINE; CLARITIN	4282233	JUN 19, 2002	U-77		
>DLT>	~~19658 001~~	~~LORATADINE; CLARITIN~~	~~4282233~~	~~AUG 04, 2000~~	~~U-77~~		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19670 001	LORATADINE; CLARITIN-D	4282233	JUN 19, 2002	U-77	NCE	APR 12, 1998
>DLT>	~~19670 001~~	~~LORATADINE; CLARITIN-D~~	~~4282233~~	~~AUG 04, 2000~~		~~NCE~~	~~APR 12, 1998~~
	20386 001	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009		NCE	APR 14, 2000
	20386 002	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009		NCE	APR 14, 2000
>ADD>	19643 002	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-117	FEB 08, 1998
>DLT>	~~19643 002~~	~~LOVASTATIN; MEVACOR~~	~~4231938~~	~~NOV 04, 1999~~		~~I-117~~	~~FEB 08, 1998~~
>ADD>	19643 003	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-117	FEB 08, 1998
>DLT>	~~19643 003~~	~~LOVASTATIN; MEVACOR~~	~~4231938~~	~~NOV 04, 1999~~		~~I-117~~	~~FEB 08, 1998~~
>ADD>	19643 004	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-117	FEB 08, 1998
>DLT>	~~19643 004~~	~~LOVASTATIN; MEVACOR~~	~~4231938~~	~~NOV 04, 1999~~		~~I-117~~	~~FEB 08, 1998~~
	19940 001	MASOPROCOL; ACTINEX	4695590	SEP 04, 2006		NCE	SEP 04, 1997
	19591 001	MEFLOQUINE HYDROCHLORIDE; LARIAM	4579855	OCT 01, 2004			
	20207 001	MELPHALAN HYDROCHLORIDE; ALKERAN	4997651	NOV 18, 2008			
	18029 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN-SR	4137300	AUG 20, 1996			
	19962 001	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
			5001161	MAR 19, 2008			
			4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
	19962 002	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
			5001161	MAR 19, 2008			
			4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
	19962 003	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
			5001161	MAR 19, 2008			
			4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
>ADD>	20531 001	METRONIDAZOLE; METROCREAM				NDF	SEP 20, 1998
	18654 001	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
	18654 002	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
	19268 001	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
	19268 003	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
>ADD>	20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	FEB 24, 2007		NCE	APR 19, 2000
>DLT>	~~20312 001~~	~~MOEXIPRIL HYDROCHLORIDE; UNIVASC~~	~~4743450~~	~~MAY 24, 2007~~		~~NCE~~	~~APR 19, 2000~~
>ADD>	20312 002	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	FEB 24, 2007		NCE	APR 19, 2000
>DLT>	~~20312 002~~	~~MOEXIPRIL HYDROCHLORIDE; UNIVASC~~	~~4743450~~	~~MAY 24, 2007~~		~~NCE~~	~~APR 19, 2000~~
	20459 001	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
	20459 002	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
	18932 001	NALTREXONE HYDROCHLORIDE; REVIA				I-129	DEC 30, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
	20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
	20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
	20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
	20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
	20152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
>ADD>	19488 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	FEB 15, 1996			
>DLT>	~~19488 001~~	~~NICARDIPINE HYDROCHLORIDE; CARDENE~~	~~3985758~~	~~OCT 12, 1995~~			
	19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	5164405	NOV 17, 2009			
			4880823	NOV 14, 2006			
>ADD>			3985758	FEB 15, 1996			
>DLT>			~~3985758~~	~~OCT 12, 1995~~			
	20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
>ADD>			3985758	FEB 15, 1996			
>DLT>			~~3985758~~	~~OCT 12, 1995~~			
	20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
>ADD>			3985758	FEB 15, 1996			
>DLT>			~~3985758~~	~~OCT 12, 1995~~			
	20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
>ADD>			3985758	FEB 15, 1996			
>DLT>			~~3985758~~	~~OCT 12, 1995~~			
	20076 001	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
	20076 002	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
	20076 003	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
	20150 001	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
	20150 002	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
	20150 003	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
	20165 001	NICOTINE; NICODERM	5364630	JUN 14, 2008			
			5344656	JUN 14, 2008			
			5342623	JUN 14, 2008			
			5004610	JUN 14, 2008			
	20165 002	NICOTINE; NICODERM	5364630	JUN 14, 2008			
			5344656	JUN 14, 2008			
			5342623	JUN 14, 2008			
			5004610	JUN 14, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20165 003	NICOTINE; NICODERM	5364630	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
19684 001	NIFEDIPINE; PROCARDIA XL	5004610	JUN 14, 2008			
19684 002	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
19684 003	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
20198 001	NIFEDIPINE; ADALAT CC	4327725	NOV 25, 2000			
		5264446	NOV 23, 2010			
20198 002	NIFEDIPINE; ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
20198 003	NIFEDIPINE; ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
20356 001	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008			
		4892741	JUN 08, 2008			
20356 002	NISOLDIPINE; NISOCOR	4154839	NOV 02, 1996		NCE	FEB 02, 2000
		4892741	JUN 08, 2008			
20356 003	NISOLDIPINE; NISOCOR	4154839	NOV 02, 1996		NCE	FEB 02, 2000
		4892741	JUN 08, 2008			
20356 004	NISOLDIPINE; NISOCOR	4154839	NOV 02, 1996		NCE	FEB 02, 2000
		4892741	JUN 08, 2008			
20064 001	NITROFURANTOIN; MACROBID	4154839	NOV 02, 1996		NCE	FEB 02, 2000
		4798725	JUN 16, 2006			
20145 001	NITROGLYCERIN; NITRO-DUR	4772473	JUN 16, 2006			
20145 002	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 003	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 004	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 005	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 006	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
19508 001	NIZATIDINE; AXID	5186938	FEB 16, 2010			
19508 002	NIZATIDINE; AXID	4375547	APR 12, 2002			
19384 002	NORFLOXACIN; NOROXIN	4375547	APR 12, 2002			
>ADD>		4639458	JAN 22, 2005			
>DLT>		4146719	FEB 16, 2000			
		4146719	MAR 27, 1998			
19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 14, 2003			
>ADD>		4146719	FEB 16, 2000			
>DLT>		4146719	MAR 27, 1998			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
	20087 002	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
	20087 003	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
	20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
	20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
	19810 001	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108		
			4786505	APR 20, 2007	U-108	I-130	JUN 22, 1998
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4255431	MAR 10, 2000	U-108		
			4753789	JUN 24, 2006	U-44		
	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 25, 2005		D-20	FEB 02, 1996
			4753789	JUN 24, 2006	U-44	D-27	APR 10, 1998
	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 25, 2005		NCE	JAN 04, 1996
						I-9	APR 19, 1998
	20403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-27	APR 10, 1998
			4695578	JAN 25, 2005		NCE	JAN 04, 1996
						I-9	APR 19, 1998
	19828 001	OXICONAZOLE NITRATE; OXISTAT	4753789	JUN 24, 2006	U-44	D-20	FEB 02, 1996
	20209 001	OXICONAZOLE NITRATE; OXISTAT	4695578	JAN 25, 2005		NCE	JAN 04, 1996
>ADD>	20036 001	PAMIDRONATE DISODIUM; AREDIA				I-9	AUG 13, 1996
>ADD>	20036 003	PAMIDRONATE DISODIUM; AREDIA	4124767	DEC 27, 1996			
>ADD>	20036 004	PAMIDRONATE DISODIUM; AREDIA	4124767	DEC 27, 1996			
	19385 001	PERGOLIDE MESYLATE; PERMAX	4711880	JUL 29, 2005		I-135	SEP 01, 1998
			4711880	JUL 29, 2005		I-135	SEP 01, 1998
	19385 002	PERGOLIDE MESYLATE; PERMAX	4711880	JUL 29, 2005		I-135	SEP 01, 1998
			4797405	OCT 26, 2007			
	19385 003	PERGOLIDE MESYLATE; PERMAX	4166182	FEB 08, 2000			
			4797405	OCT 26, 2007			
	17850 001	POTASSIUM CHLORIDE; KLOTRIX	4166182	FEB 08, 2000			
	18238 001	POTASSIUM CHLORIDE; MICRO-K	4797405	OCT 26, 2007			
	18238 002	POTASSIUM CHLORIDE; MICRO-K 10	4166182	FEB 08, 2000			
	19561 003	POTASSIUM CHLORIDE; MICRO-K LS	4140756	JUN 10, 1996			
	19775 001	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4259315	JUN 13, 2000			
	19775 002	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4259315	JUN 13, 2000			
			4259315	JUN 13, 2000			
			4327725	NOV 25, 2000			
			4327725	NOV 25, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19627 001	PROPOFOL; DIPRIVAN	4798846	MAR 19, 1997			
>DLT>	~~19627 001~~	~~PROPOFOL; DIPRIVAN~~	~~4798846~~	~~NOV 01, 1996~~			
>ADD>			4056635	MAR 19, 1997			
>DLT>			~~4056635~~	~~NOV 01, 1996~~			
	18553 001	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
	18553 002	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
	18553 003	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
	18553 004	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
	19536 001	PROPRANOLOL HYDROCHLORIDE; INDERAL	4600708	JUL 19, 2005			
	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	4929605	OCT 07, 2007	U-81		
			4254129	APR 10, 1999	U-81		
	20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24	4801461	MAR 14, 2006			
	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
			4344949	AUG 17, 2001	U-3		
	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
			4344949	AUG 17, 2001	U-3		
	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
			4344949	AUG 17, 2001	U-3		
	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
			4344949	AUG 17, 2001	U-3		
	19901 001	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
	19901 002	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
	19901 003	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
	19901 004	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4880636	MAY 13, 2008			
			4128658	JUL 25, 1997		I-120	MAR 29, 1998
	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4880636	MAY 13, 2008			
			4128658	JUL 25, 1997		I-120	MAR 29, 1998
	19090 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
			4128658	JUL 25, 1997			
	19593 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4128658	JUL 25, 1997			
>ADD>	19593 002	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	APR 29, 2003			
>ADD>			4521431	JUN 04, 2002			
			4128658	JUL 25, 1997			
	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	FEB 22, 2010		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	FEB 22, 2010		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	APR 13, 2008			
	20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	APR 13, 2008			
	20236 001	SALMETEROL XINAFOATE; SEREVENT	5380922	MAY 14, 2013			
	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	20478 001	SEVOFLURANE; ULTANE				NCE	JUN 07, 2000
	19766 001	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19766 002	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19766 003	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19766 004	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
>ADD>	19721 001	SOMATROPIN; NORDITROPIN				NS	MAY 08, 1998
>ADD>	19721 002	SOMATROPIN; NORDITROPIN				NS	MAY 08, 1998
	20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20070 001	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
			4631286	OCT 25, 2004	U-97		
	20070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
			4631286	OCT 25, 2004	U-97		
	20070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
			4631286	OCT 25, 2004	U-97		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
			4631286	OCT 25, 2004	U-97		
	19829 001	TECHNETIUM TC-99M EXAMETAZIME KIT; CERETEC	4789736	DEC 06, 2005		I-124	APR 07, 1998
>ADD>			4615876	OCT 07, 2003			
>DLT>			~~4615876~~	~~MAR 14, 2008~~			
>ADD>	19981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG	4755375	JUL 05, 2005	U-51		
>DLT>	~~19981 001~~	~~TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG~~	~~4755375~~	~~APR 17, 2008~~	~~U-51~~		
	19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
	19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4112097	JAN 21, 1997	U-3		
			5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
	19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4112097	JAN 21, 1997	U-3		
			5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
	19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4112097	JAN 21, 1997	U-3		
			5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
	20347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4112097	JAN 21, 1997	U-3		
			5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
	20347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4112097	JAN 21, 1997			
			5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
>ADD>	20347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4112097	JAN 21, 1997			
>DLT>	~~20347 003~~	~~TERAZOSIN HYDROCHLORIDE; HYTRIN~~	5412095	APR 29, 2013			
			~~5412095~~	~~MAR 15, 2011~~			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
			4112097	JAN 21, 1997			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN					
			5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
	18949 001	TERFENADINE; SELDANE	4112097	JAN 21, 1997			
>ADD>	20489 001	TESTOSTERONE; ANDRODERM	4254129	APR 10, 1999	U-81		
	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID				NS	SEP 29, 1998
	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
	20439 001	TIMOLOL; BETIMOL	4591592	MAY 27, 2003			
	20439 002	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
>ADD>	20136 001	TORSEMIDE; DEMADEX	5231095	JUL 27, 2010		NP	MAR 31, 1998
>DLT>			RE34672	AUG 11, 2006			
>ADD>	20136 002	TORSEMIDE; DEMADEX	~~4822807~~	~~AUG 11, 2006~~			
>DLT>			RE34672	AUG 11, 2006			
>ADD>	20136 003	TORSEMIDE; DEMADEX	~~4822807~~	~~AUG 11, 2006~~			
>DLT>			RE34672	AUG 11, 2006			
>ADD>	20136 004	TORSEMIDE; DEMADEX	~~4822807~~	~~AUG 11, 2006~~			
>DLT>			RE34672	AUG 11, 2006			
>ADD>	20137 002	TORSEMIDE; DEMADEX	~~4822807~~	~~AUG 11, 2006~~			
>ADD>			4861786	JUL 08, 2007			
>DLT>			RE34672	AUG 11, 2006			
			~~4822807~~	~~AUG 11, 2006~~			
	20281 001	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
	20281 002	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
	18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
			4215104	MAR 26, 1999			
	18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
			4215104	MAR 26, 1999			
	19798 001	TRIAMCINOLONE ACETONIDE; NASACORT	4767612	JAN 23, 2007	U-85		
	20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	MAY 20, 2006	U-91		
			4376858	OCT 31, 2000			
	20487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	SEP 18, 2007		NE	JUN 23, 1998
	20487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	SEP 18, 2007		NE	JUN 23, 1998
	18776 002	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
			4237126	AUG 20, 1999			
	18776 003	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
			4237126	AUG 20, 1999			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
19614 001	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
19614 002	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
19614 003	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
20388 001	VINORELBINE TARTRATE; NAVELBINE	4307100	NOV 23, 2001		NCE	DEC 23, 1999
19655 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
19910 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
19951 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			

*U.S. Government Printing Office: 1995 - 404-907/20003

New 16th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7809

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

___ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $72.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

( ) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature)

(10/95)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.